

Withdrawal/Redaction Sheet

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. email	From: Webwolf@teleport.com, To: Jeffrey Levi, Re: What Up? (2 pages)	07/18/1996	Personal Misfile
002. email	From: Jeffrey Levi, To: Webwolf@teleport.com, Re: What Up? (1 page)	07/18/1996	Personal Misfile
003. email	From: Mail Link Monitor, To: Jeffrey Levi, Re: Confirmation: Appt. Request for Klein, Jennifer L [Personally Identifiable Information] [partial] (1 page)	07/19/1996	b(7)(C), b(7)(F), b(6)
004. email	From: Jeffrey Levi, To: Jeffrey Levi, Re: Appt. Request - Smothermon, MC [Personally Identifiable Information] [partial] (1 page)	07/19/1996	b(6)
005. email	From: Mail Link Monitor, To: Jeffrey Levi, Re: Confirmation: Appt. Request for Donenfeld, Toby A [Personally Identifiable Information] [partial] (1 page)	07/19/1996	b(7)(C), b(7)(F), b(6)
006. email	From: Jeffrey Levi, To: Jeffrey Levi, Re: Appt. Request - Smothermon, MC [Personally Identifiable Information] [partial] (1 page)	07/19/1996	b(6)
007. email	From: Donald Abrams, To: Jeffrey Levi, Re: Has there been a Novick Siting? (1 page)	07/20/1996	Personal Misfile
008. email	From: Carol Rasco, To: Jeffrey Levi, Re: Two Things [personal] [partial] (1 page)	07/21/1996	b(6)
009. email	From: Jeffrey Levi, To: Donald Abrams, Re: Has there been a Novick Siting? (1 page)	07/21/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

in423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Sheet

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
010. email	From: Donald Abrams, To: Jeffrey Levi, Re: The Novick Saga (1 page)	07/22/1996	Personal Misfile
011. email	From: Jeffrey Levi, To: Kaplan@mppm.som.yale.edu, Re: Novick is Alive and Well (1 page)	07/22/1996	Personal Misfile
012. email	From: Jeffrey Levi, To: Ursula Sanville, Re: Trying Again [personal] [partial] (1 page)	07/22/1996	b(6)
013. email	From: Edward Kaplan, To: Jeffrey Levi, Re: Novick is Alive and Well (2 pages)	07/23/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

in423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto (PIZZUTO_J) (OPD)

CREATION DATE/TIME:16-JUL-1996 10:25:09.26

SUBJECT: CHR Highlights

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:16-JUL-1996 11:24:43.39

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:16-JUL-1996 15:44:19.45

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:16-JUL-1996 12:07:24.04

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:16-JUL-1996 11:01:45.96

TO: Denise Ricketson (RICKETSON_D) (OPD)
READ:16-JUL-1996 10:31:50.99

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:16-JUL-1996 10:53:47.73

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:16-JUL-1996 10:25:52.88

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:16-JUL-1996 12:58:10.44

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:16-JUL-1996 11:52:17.51

TO: Carol H. Rasco (RASCO_C) Autoforward to: Jill Pizzuto (PIZZUTO_J) (WHO)
READ:NOT READ

TO: Janet B. Abrams (ABRAMS_J) (VPO)
READ:NOT READ

TO: Dorothy L. Karayannis (KARAYANNIS_D)
READ:NOT READ

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 15:53:13.02

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:16-JUL-1996 11:19:22.92

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:16-JUL-1996 14:44:17.65

TO: Deborah L. Fine (FINE_D) (OPD)
READ:16-JUL-1996 11:03:56.83

TO: Dennis Burke (BURKE_D) (OPD)
READ:16-JUL-1996 11:05:18.97

TO: Diane Regas (REGAS_D) (OPD)
READ:16-JUL-1996 12:18:59.11

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:NOT READ

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:16-JUL-1996 11:39:12.58

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:16-JUL-1996 15:04:03.22

TO: FAX (9-720-4732,Elworth, Larry) (TLXA1MAIL_ \F:9-720-4732\C:Elworth, Larry\\)
READ:NOT READ

IND_TO: Dorothy K. Craft (CRAFT_D) (OPD)
READ:26-JUL-1996 08:29:51.41

TEXT:
fyi staff: Carol is due back this evening - will be stopping by
the office for an evening appoint she's got here (7:30p). She
will be in the office for the remainder of the week. I'll be
sending around reminder notes to appropriate staffers re:
meetings and/or whether or not I should expect anything for her
briefing book.
if you have any questions, please call or email me. THANKS.

PRINTER FONT 12_POINT_ROMAN
TO: DPC STAFF
FR: JILL PIZZUTO
RE: CHR CALENDAR HIGHLIGHTS

July 17:
9:00 a. Keynote Address: Effective Employment Strategies for
Individuals with Disabilities
Conference (US Dept of Education/Rehabilitation Services
Administration)
2

-4:00p Partnerships Steering Committee Meeting
July 18:
12

-2:30p Coalition for America's Children Luncheon, Willard Grand
Ballroom
3

-5:00p Child Welfare Meeting

5:00p Cabinet Meeting (w/ Mrs. Alma (Ron) Brown)

July 19 OR 20 TO August 6th:

Personal Leave

** NOTE: the next three weeks are not finalized. thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:16-JUL-1996 11:38:53.52

SUBJECT: National strategy

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:16-JUL-1996 12:48:22.34

TEXT:

Do we know anything about whether the scheudlign request has been reviewed, etc.? thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeremy D. Benami (BENAMI_J) (WHO)

CREATION DATE/TIME: 17-JUL-1996 17:31:04.38

SUBJECT: AIDS meeting with POTUS

TO: Jeffrey Levi (LEVI_J) (WHO)

READ: 17-JUL-1996 18:33:46.11

TO: Carol H. Rasco (RASCO_C) (WHO)

READ: 17-JUL-1996 17:39:17.43

CC: Patsy Fleming (FLEMING_P) (WHO)

READ: 24-JUL-1996 15:54:16.28

TEXT:

(1) Jeff: The Scheduling Request for the Cabinet meeting needs to be redone from Kitty Higgins and Carol jointly. Can you please get it regenerated with Kitty as a co-signatory and fax it to Steve Silverman in Cabinet Affairs. I have a call into him to discuss.

(2) George is interested in having the President make a big fuss over the AIDS \$ -- he even was talking radio address. Carol: he said you should definitely bring it up at 7:30. I have not gotten feedback from Don yet, however. Jeff: you should be sure that it is on hold for HHS announcement - this should definitely not just appear out of nowhere!!

(3) I have not heard, Jeff, from you or HHS re National Strategy this week. I assume that means we are set on HHS sign-off and that you don't need me to call a meeting. Let me know if we're still on track to go to the printer on Monday.

Thanks.

P.S. Please tell Richard I returned his call. I don't think I can cc him on email, can I?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:17-JUL-1996 10:09:47.55

SUBJECT: CO and CA hot issues

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:NOT READ

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:17-JUL-1996 17:18:29.55

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:17-JUL-1996 10:15:33.20

TO: Dennis Burke (BURKE_D) (OPD)
READ:18-JUL-1996 10:26:01.71

TO: Diane Regas (REGAS_D) (OPD)
READ:17-JUL-1996 10:09:59.46

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:NOT READ

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:17-JUL-1996 11:21:14.16

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:17-JUL-1996 11:23:40.04

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:17-JUL-1996 14:21:59.35

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:17-JUL-1996 10:26:16.70

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:17-JUL-1996 10:11:12.69

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:17-JUL-1996 10:14:39.75

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:17-JUL-1996 12:00:36.89

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:17-JUL-1996 10:19:21.75

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:17-JUL-1996 10:15:40.64

TO: Michael Cohen (COHEN_M) (OPD)
READ:17-JUL-1996 12:21:41.83

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:17-JUL-1996 18:52:06.72

TEXT:

Please let me know at 9:30 tomorrow of any issues we or others should write up for President's Denver/LA/San Francisco/Sacramento briefing book. Thanks.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 09:39:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Phillip M. Caplan

ATT SUBJECT: Colorado/California issues meeting

ATT TO: Stephen B. Silverman (SILVERMAN_S)

ATT TO: Loreen M. Keller (KELLER_L)

ATT TO: Ann F. Walker (WALKER_A)

ATT TO: Victoria L. Radd (RADD_V)

ATT TO: Elizabeth E. Drye (DRYE_E)

ATT TO: Shelley N. Fidler (FIDLER_S)

ATT TO: Brian J. Johnson (JOHNSON_BJ)

ATT TO: Kevin P. Varney (VARNEY_K)

ATT TO: Michael Warren (WARREN_M)

ATT TO: Karen L. Hancox (HANCOX_K)

ATT TO: Ray Martinez (MARTINEZ_R)

ATT TO: John B. Emerson (EMERSON_J)

ATT TO: Lucie F. Naphin (NAPHIN_L)

ATT TO: Patrick M. Steel (STEEL_P)

ATT TO: Andrew Friendly (FRIENDLY_A)

ATT TO: Lee A. Satterfield (SATTERFIEL_L)

ATT TO: Mary Ellen Glynn (GLYNN_M)

ATT TO: Ann M. Cattalini (CATTALINI_A)

ATT TO: Emily Bromberg (BROMBERG_E)

ATT TO: John C. Angell (ANGELL_J)

ATT CC: Todd Stern (STERN_T)

ATT CC: Helen P. Howell (HOWELL_H)

TEXT:

There will be a meeting at 11:00 am tomorrow, July 18, in the Staff Secretary's office to review issues for the upcoming 3-day Colorado/California trip. Please come prepared to discuss issues in your area for which the President may need briefing.

Thanks.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:17-JUL-1996 12:58:03.69

SUBJECT: RE: Use of ITR on Aug. 12

TO: Kim Holmes (HOLMES_K) (WHO)

READ:17-JUL-1996 14:32:56.42

TEXT:

thanks very much. who do we talk to about making arrangements,
making sure the invite meets these requirements, etc.?

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Kinseyvi@aol.com@INET@EOPMRX

CREATION DATE/TIME:17-JUL-1996 16:16:00.00

SUBJECT: Fwd: Re: Letter to Helene Gayle

TO: Levi_J (Levi_J@A1@CD) (WHO)
READ:18-JUL-1996 08:14:12.12

TEXT:
As I suspected...

XOXO

Ben

Forwarded message:

Subj: Re: Letter to Helene Gayle
Date: 96-07-16 20:34:38 EDT
From: Lamda23
To: Kinseyvi

Yes, you are right. All of these cases are post July, 1991.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 16:16:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01176OWSCGTS000K7Q@PMDF.EOP.GOV> for
Levi_J@a1.eop.gov; Wed, 17 Jul 1996 16:15:54 -0400 (EDT)
Received: from emout08.mail.aol.com (emout08.mx.aol.com)
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01176OWHB57U00007U@STORM.EOP.GOV> for
Levi_J@a1.eop.gov; Wed, 17 Jul 1996 16:15:45 -0700 (MST)
Received: by emout08.mail.aol.com (8.6.12/8.6.12)
id QAA07759 for Levi_J@a1.eop.gov; Wed, 17 Jul 1996 16:16:59 -0400
===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeremy D. Benami (BENAMI_J) (WHO)

CREATION DATE/TIME:17-JUL-1996 19:07:57.09

SUBJECT: erd email

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:18-JUL-1996 08:16:26.12

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 19:02:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Patricia M. McMahon

ATT SUBJECT: RE: AIDS Strategy

ATT TO: Jeremy D. Benami (BENAMI_J)

TEXT:

Thanks Jeremy

Barbara Roberts is working on it

Will check with her tomorrow

Ricia

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Kim Holmes (HOLMES_K) (WHO)

CREATION DATE/TIME:17-JUL-1996 14:32:54.07

SUBJECT: RE: Use of ITR on Aug. 12

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:17-JUL-1996 18:33:24.31

TEXT:

call x62500 to make final reservations for the room although I have tentatively scheduled it for you. To make sure about the reservation, you should have counsel's office take a look at it.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:17-JUL-1996 12:58:39.59

SUBJECT: so we keep things in one circle --

TO: Jennifer L. Klein (KLEIN_J) (OPD)

READ:17-JUL-1996 14:25:20.30

TEXT:

I know Tim had spoken with you about this as well...but I assume
this helps close the loops. jeff

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:17-JUL-1996 10:49:57.23

SUBJECT: welfare reform

TO: Carol H. Rasco (RASCO_C) (WHO)

READ:17-JUL-1996 10:52:28.90

TEXT:

Tim Westmoreland has raised the concern about coverage of women and kids for Medicaid under the pending welfare reform bill.

Since most women and kids with HIV get eligibility for Medicaid first through their being on AFDC -- and since the federal standard for AFDC would no longer exist -- how can we be sure that this population continues to have Medicaid eligibility. (This is particularly important for prevention of perinatal transmission -- for example.)

We have entered an area -- welfare reform -- far beyond my realm of knowledge -- but protecting eligibility for Medicaid has been one of our strong points with the AIDS community and this seems like a real threat to a critical population.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:17-JUL-1996 21:49:38.62

SUBJECT: attachments

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:18-JUL-1996 12:28:30.36

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:NOT READ

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 21:43:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Ursula Sanville

TEXT:

PRINTER FONT 12_POINT_ROMAN

May 23, 1996

MEMORANDUM FOR THE INTERDEPARTMENTAL TASK FORCE ON HIV/AIDS,
DEPARTMENT OF ENERGY

FROM: Patricia S. Fleming

Director, Office of National AIDS Policy

SUBJECT: Update of Budget Figures for the National Strategy for
HIV and AIDS

As you remember, as a result of our meetings last year each member of the Interdepartmental Task Force on HIV/AIDS (IDTF) was asked to develop individual department and agency plans for HIV/AIDS, linking goals and objectives to budget levels and identifying areas of unmet need.

This past February, IDTF members reviewed the draft and provided comment. We are in the final stages of revising the document as informed by this review. Attached is the final language for the Department of Energy appendix, based on DOE's comments.

Comments are due back to the Office of National AIDS Policy BY NO LATER THAN MAY 31, 1996. If you have any questions please call Jane Sanville at (202) 632

-1090.

Thank you for your assistance in developing this first

-ever

National Strategy for HIV and AIDS.

Attachment: Department of Energy Appendix for National
Strategy on HIV and AIDS.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:17-JUL-1996 10:50:23.12

SUBJECT: forgot to list you on this...sorry

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:17-JUL-1996 12:36:59.50

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 10:26:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jeffrey Levi

ATT SUBJECT: welfare reform

ATT TO: Carol H. Rasco (RASCO_C)

TEXT:

Tim Westmoreland has raised the concern about coverage of women and kids for Medicaid under the pending welfare reform bill.

Since most women and kids with HIV get eligiblity for Medicaid first through their being on AFDC -- and since the federal standard for AFDC would no longer exist -- how can we be sure that this population continues to have Medicaid eligiblity. (This is particularly important for prevention of perinatal transmission -- for example.)

We have entered an area -- welfare reform -- far beyond my realm of knowledge -- but protecting eligibility for Medicaid has been one of our strong points with the AIDS community and this seems like a real threat to a critical population.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jennifer L. Klein (KLEIN_J) (OPD)

CREATION DATE/TIME:17-JUL-1996 14:25:16.09

SUBJECT: RE: so we keep things in one circle --

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:17-JUL-1996 18:33:07.10

TEXT:

Chris and I just briefed Carol on this. Give me a call and I will fill you in on what we are doing. Everyone here is very much in agreement that we need to maintain Medicaid coverage.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeremy D. Benami (BENAMI_J) (WHO)

CREATION DATE/TIME:17-JUL-1996 19:05:19.75

SUBJECT: oops sent wrong email you'll figure this out

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:18-JUL-1996 08:15:46.90

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 18:58:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jeremy D. Benami

ATT SUBJECT: RE: AIDS Strategy

ATT TO: Patricia M. McMahon (MCMAHON_P)

TEXT:

Yes.

The AIDS Strategy MUST be at the printer on Monday. I realize that ONDCP may now have a problem with what Fred did previously, but it would be really great if whatever changes you need made could be given to the AIDS office ASAP or faster!! We are so late in getting this done, the deadlines can't slip any further!

Thanks.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Kim Holmes (HOLMES_K) (WHO)

CREATION DATE/TIME:17-JUL-1996 11:12:13.66

SUBJECT: Use of ITR on Aug. 12

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:17-JUL-1996 12:54:28.87

TEXT:

I have conferred with Jodie Torkelson about your use of the ITR on August 12. You may use the room and co-sponsor the event. Whoever pays for the event is the host and therefore must be the one getting credit for the invitation. The WH cannot invite people to a WH event and have someone else pay for it, for example. She just wanted to make sure that you understood that. Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeremy D. Benami (BENAMI_J) (WHO)

CREATION DATE/TIME:17-JUL-1996 19:04:41.08

SUBJECT: Ricia's email

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:18-JUL-1996 08:15:37.88

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 18:36:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Patricia M. McMahon

ATT SUBJECT: AIDS Strategy

ATT TO: Jeremy D. Benami (BENAMI_J)

ATT CC: Dennis Burke (BURKE_D)

TEXT:

ONDCP has been asked to review a segment of the AIDS Strategy that was generated by Fred Garcia months ago. The Strategy is being developed and coordinated by Patsy Fleming's office. The draft of our segment had much needed review and revision. Our staff is rewriting.

DPC may also be working on a review of the current document, hopefully of the total revision. ONDCP and OMB will need to take a final chop at it.

Staff from AIDS Policy wanted to get the document to the printer next week in order to provide the final strategy to POTUS in a couple of weeks.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME: 17-JUL-1996 21:49:47.21

SUBJECT: attachments III

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ: 18-JUL-1996 13:47:11.49

TO: Jeffrey Levi (LEVI_J) (WHO)
READ: NOT READ

TEXT:

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE: 17-JUL-1996 21:46:00.00

ATT BODYPART TYPE: p

ATT CREATOR: Ursula Sanville

TEXT:

PRINTER FONT 12_POINT_ROMAN
July 16, 1996

MEMORANDUM TO THE SECRETARY OF STATE

FROM: PATRICIA S. FLEMING

SUBJECT: Clearance request for the National Strategy on HIV and AIDS

I am requesting your clearance of the National Strategy for HIV and AIDS. I need your final clearance by July 22, 1996.

The National Strategy for HIV and AIDS has been developed to capitalize on progress that has been made in combatting the epidemic and catalyze improved collaborative efforts among Federal Departments and Agencies, communities, State and local governments, and the private sector.

As a result of our meetings last year each member of the Interdepartmental Task Force on HIV/AIDS (IDTF) developed individual plans for HIV/AIDS, linking goals and objectives to budget levels and identifying areas of unmet need. This past February, IDTF members reviewed the draft and provided comment. The document was revised based on these comments and circulated again for final review.

The portions of the document relevant to the State Department have been developed in collaboration with Anne K. Solomon, Deputy Assistant Secretary for Science, Technology, and Health. The State Department's sections were based on the Department's United States International Strategy on HIV/AIDS (July 1995) and information provided by Ms. Solomon's staff.

Attached is the final language for the Department of State's appendix and the main text of the National Strategy. Ms. Solomon has seen this document and had no further comments, as communicated in her letter of July 3, 1996.

Your timely review and clearance of this document is appreciated. Please send your clearance using the attached form to Jane Sanville at fax 202

-632

-1906, phone 202

-632

-1090.

Thank you for your assistance in developing this first

-ever

National Strategy for HIV and AIDS.

THE OFFICE OF NATIONAL AIDS POLICY
CONCURRENCE SHEET

RETURN BY MONDAY, JULY 22, 1996

Please check the applicable box and sign in space provided.

THE NATIONAL STRATEGY FOR HIV AND AIDS

- ☐ a. I approve the National Strategy for HIV and AIDS
☐ b. I approve the National Strategy for HIV and AIDS with
minor editing (attach comments)

Signature	Department	Date
Telephone #		

Return by FAX to:
Jane Sanville
202

-632

-1096

FAILURE TO RESPOND BY JULY 22, 1996 PRESUMES CONCURRENCE
===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:17-JUL-1996 21:49:42.90

SUBJECT: attachment II

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:18-JUL-1996 13:47:09.37

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:NOT READ

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 21:44:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Ursula Sanville

TEXT:

PRINTER FONT 12_POINT_COURIER

RESEARCH

Agency: Department of Energy

Goal: Provide infrastructure support for physical chemical research, termed structural biology, including indirect support for HIV

-related research.

Objective: In collaboration with other Federal agencies, provide access to sophisticated equipment and specially trained scientific personnel.

Action Steps: In collaboration with all relevant agencies (NIH, NSF, DOE) and the scientists they support, provide continued essential support for structural chemistry and biology facilities. Provide both the academic and the industrial community access to the facilities for further studies on the structural biology of HIV.

Descriptions: The National Synchrotron Light Source at Brookhaven National Laboratory includes a Department of Energy supported

x

-ray beam line extensively used by structural biologists studying virus structure, including the structure of HIV. In addition, through its National Laboratory system, DOE provides user facilities at other synchrotron light sources and at neutron beam facilities, which can be used by researchers to characterize the structural configuration of intact HIV , and HIV's biochemical components, often in complexes with inhibitors. These studies assist in the development of novel therapies, as

well as advance our understanding of the pathogenesis and
fundamental biology of HIV growth.

FY 95: Part of DOE's general operating budget.

FY 96: Part of DOE's general operating budget.

FY 97: Part of DOE's general operating budget.

Populations Served: Scientific community.

Constituency Involvement: Access to resources through peer
review.

Unmet Need: Stable funding, guaranteed access for scientists to
the facilities for the foreseeable future.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeremy D. Benami (BENAMI_J) (WHO)

CREATION DATE/TIME:17-JUL-1996 19:00:24.28

SUBJECT: fyi

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:18-JUL-1996 08:14:23.12

TEXT:

fyi

response to an email I will now send you

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 18:36:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Patricia M. McMahon

ATT SUBJECT: AIDS Strategy

ATT TO: Jeremy D. Benami (BENAMI_J)

ATT CC: Dennis Burke (BURKE_D)

TEXT:

ONDCP has been asked to review a segment of the AIDS Strategy that was generated by Fred Garcia months ago. The Strategy is being developed and coordinated by Patsy Fleming's office. The draft of our segment had much needed review and revision. Our staff is rewriting.

DPC may also be working on a review of the current document, hopefully of the total revision. ONDCP and OMB will need to take a final chop at it.

Staff from AIDS Policy wanted to get the document to the printer next week in order to provide the final strategy to POTUS in a couple of weeks.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:18-JUL-1996 16:45:56.66

SUBJECT: WEEKLY IS DUE IN AN HOUR> THANKS>>>> VERY MUCH

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:18-JUL-1996 18:36:36.32

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:18-JUL-1996 19:31:03.00

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:18-JUL-1996 17:54:12.46

TO: Dennis Burke (BURKE_D) (OPD)
READ:24-JUL-1996 07:54:23.57

TO: Diane Regas (REGAS_D) (OPD)
READ:18-JUL-1996 17:20:54.30

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:NOT READ

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:18-JUL-1996 17:00:21.34

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:19-JUL-1996 08:21:11.15

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUL-1996 20:00:09.35

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:18-JUL-1996 16:46:37.91

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:18-JUL-1996 17:13:19.02

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:18-JUL-1996 17:31:50.47

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:18-JUL-1996 17:32:12.76

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:18-JUL-1996 18:28:38.78

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:18-JUL-1996 17:33:55.62

TO: Michael Cohen (COHEN_M) (OPD)
READ:18-JUL-1996 17:35:42.76

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:19-JUL-1996 16:44:23.79

TEXT:

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 11:41:43.86

SUBJECT: AIDS drug \$

TO: Carol H. Rasco (RASCO_C) (WHO)

READ:18-JUL-1996 11:43:03.84

CC: Jeremy D. Benami (BENAMI_J) (WHO)

READ:18-JUL-1996 12:29:23.27

CC: Elizabeth E. Drye (DRYE_E) (OPD)

READ:18-JUL-1996 12:00:16.67

TEXT:

I met with Nancy-Ann this morning; HHS is still resisting a real offset (they are proposing an IHS offset that is not real -- and can't be done since it's from a different bill). If Nancy-Ann cannot work this out with John Callahan of ASMB, she will call you to help with the Secretary.

Nancy-Ann will also be preparing a memo from Jack Lew to the President -- and will speak to you about co-signing -- explaining how much we are proposing (about \$65 million), and where the offsets will be coming from -- so there are no surprises.

I should make clear that there is general agreement that more money IS needed for this program -- at approximately this level. We also thought, yesterday morning, that we had an agreement on the offsets.

I will be out of the office until 3 -- but can be paged.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Douglas Band (BAND_D) (WHO)

CREATION DATE/TIME:18-JUL-1996 14:21:53.47

SUBJECT: Steve's Farewell Fiesta

TO: Debra A. Schiff (SCHIFF_D) (WHO)
READ:18-JUL-1996 17:51:17.42

TO: Thomas F. McLarty (MCLARTY_T) (WHO)
READ:NOT READ

TO: Steve Ronnel (RONNEL_S) (WHO)
READ: 6-AUG-1996 11:12:03.27

TO: Patricia A. McHugh (MCHUGH_P) (WHO)
READ:18-JUL-1996 14:54:24.08

TO: Molly Varney (VARNEY_M) (WHO)
READ:18-JUL-1996 14:24:14.51

TO: John C. Angell (ANGELL_J) (WHO)
READ:18-JUL-1996 14:24:20.36

TO: Martha Foley (FOLEY_M) (WHO)
READ:18-JUL-1996 16:21:09.92

TO: Jennifer M. O'Connor (OCONNOR_J) (WHO)
READ:18-JUL-1996 20:12:28.29

TO: Rahm Emanuel (EMANUEL_R) (WHO)
READ:NOT READ

TO: Michelle Crisci (CRISCI_M) (WHO)
READ:18-JUL-1996 14:26:25.76

TO: George Stephanopoulos (STEPHANOPO_G) Autoforward to: Laura Capps (CAPPS_L) (WHO)
READ:18-JUL-1996 14:37:00.54

TO: Laura Capps (CAPPS_L) (WHO)
READ:18-JUL-1996 14:37:00.54

TO: Donald A. Baer (BAER_D) Autoforward to: Kevin Moran (MORAN_K1) (WHO)
READ:18-JUL-1996 14:34:46.65

TO: Victoria L. Radd (RADD_V) (WHO)
READ:18-JUL-1996 14:31:41.90

TO: Michael Waldman (WALDMAN_M) (WHO)
READ:18-JUL-1996 14:24:03.68

TO: James T. Edmonds (EDMONDS_J) (WHO)
READ:22-JUL-1996 09:05:30.82

TO: Jonathan M. Prince (PRINCE_J) (WHO)
READ:18-JUL-1996 14:23:47.98

TO: Ann F. Walker (WALKER_A) (WHO)
READ:18-JUL-1996 15:51:54.43

TO: David Shipley (SHIPLEY_D) (WHO)
READ:18-JUL-1996 14:31:46.40

TO: Kathryn Higgins (HIGGINS_K) Autoforward to: Elizabeth M. Toohey (TOOHEY_E)
(WHO)
READ:18-JUL-1996 15:12:39.46

TO: Stephen B. Silverman (SILVERMAN_S) (WHO)
READ:18-JUL-1996 17:03:56.81

TO: Margaret A. Williams (WILLIAMS_MA) Autoforward to: Evan M. Ryan (RYAN_E)
(WHO)
READ:18-JUL-1996 14:36:04.45

TO: Nicole R. Rabner (RABNER_N) (WHO)
READ:18-JUL-1996 15:00:55.68

TO: G. N. Lattimore (LATTIMORE_G) (WHO)
READ:NOT READ

TO: Karen Finney (FINNEY_K) (WHO)
READ:18-JUL-1996 16:02:05.88

TO: Robyn G. Dickey (DICKEY_R) (WHO)
READ:18-JUL-1996 15:46:24.63

TO: Carolyn C. Huber (HUBER_C) (WHO)
READ:30-JUL-1996 16:35:05.18

TO: John B. Emerson (EMERSON_J) (WHO)
READ:18-JUL-1996 20:17:01.73

TO: John P. Hart (HART_J) (WHO)
READ:18-JUL-1996 14:37:11.73

TO: Megan B. Williams (WILLIAMS_M) (WHO)
READ:18-JUL-1996 14:42:56.51

TO: Tracey E. Thornton (THORNTON_T) (WHO)
READ:18-JUL-1996 15:36:50.19

TO: Susan Brophy (BROPHY_S) Autoforward to: Stacey L. Rubin (RUBIN_S) (WHO)
READ:22-JUL-1996 12:40:55.35

TO: Eric Eve (EVE_E) (WHO)
READ:18-JUL-1996 14:27:41.88

TO: Ray Martinez (MARTINEZ_R) (WHO)
READ:18-JUL-1996 14:22:56.93

TO: Amanda Crumley (CRUMLEY_A) (WHO)
READ:18-JUL-1996 14:21:44.77

TO: Stacy L. Forster (FORSTER_S) (WHO)
READ:18-JUL-1996 14:21:53.42

TO: Bob J. Nash (NASH_B) (WHO)
READ:18-JUL-1996 17:51:25.37

TO: Patsy L. Thomasson (THOMASSON_P) (WHO)
READ:18-JUL-1996 20:49:36.03

TO: Peggy A. Clark (CLARK_PA) (WHO)
READ:18-JUL-1996 14:22:00.64

TO: Lorraine McHugh (MCHUGH_L) (WHO)
READ:18-JUL-1996 15:20:30.93

TO: Mary Ellen Glynn (GLYNN_M) (WHO)
READ:18-JUL-1996 17:05:12.54

TO: Virginia M. Terzano (TERZAN_V) (VPO)
READ:18-JUL-1996 16:25:29.80

TO: Kathy McKiernan (MCKIERNAN_K) (WHO)
READ:18-JUL-1996 16:36:36.55

TO: David M. Strauss (STRAUS_D) Autoforward to: Remote Addressee (David M.
Strauss@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Lorraine A. Voles (VOLES_L) Autoforward to: Remote Addressee (Lorraine A.
Voles@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Gregory C. Simon (SIMON_G) Autoforward to: Remote Addressee (Gregory C.
Simon@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Johnathan H. Spalter (SPALTE_J) Autoforward to: Remote Addressee (Jonathan
Spalter@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Kumiki S. Gibson (GIBSON_K) Autoforward to: Remote Addressee (Kumiki S.
Gibson@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Ron Klain (KLAIN_R) Autoforward to: Remote Addressee (Ron

Klain@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: Skila S. Harris (HARRIS_S) Autoforward to: Remote Addressee (Skila S.
Harris@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TO: APRIL K. MELLODY (MELLODY_A) (WHO)
READ:18-JUL-1996 14:26:04.53

TO: Patricia F. Lewis (LEWIS_PF) (WHO)
READ:18-JUL-1996 14:44:09.62

TO: Doris O. Matsui (MATSUI_D) (WHO)
READ:18-JUL-1996 17:59:11.34

TO: Floydetta McAfee (MCAFEE_F) (WHO)
READ:18-JUL-1996 15:20:06.20

TO: Jay K. Footlik (FOOTLIK_J) (WHO)
READ:18-JUL-1996 16:08:02.07

TO: Craig Gardenswartz (GARDENSWAR_C) (WHO)
READ:18-JUL-1996 14:25:08.48

TO: Stephanie Streett (STREETT_S) Autoforward to: Mary H. Morrison (MORRISON_M)
(WHO)
READ:18-JUL-1996 14:33:11.26

TO: Todd Stern (STERN_T) (WHO)
READ:18-JUL-1996 15:48:00.81

TO: Phillip M. Caplan (CAPLAN_P) (WHO)
READ:18-JUL-1996 14:33:07.73

TO: James A. Dorskind (DORSKIND_J) (WHO)
READ:18-JUL-1996 14:22:20.16

TO: Daniel W. Burkhardt (BURKHARDT_D) (WHO)
READ:18-JUL-1996 17:04:32.43

TO: G. Timothy Saunders (SAUNDERS_GT) (WHO)
READ:18-JUL-1996 14:22:17.85

TO: Sara C. Emery (EMERY_S) (WHO)
READ:18-JUL-1996 16:07:33.73

TO: William W. McCathran (MCCATHRAN_W) (WHO)
READ:18-JUL-1996 14:36:58.33

TO: Terry W. Good (GOOD_T) (WHO)
READ:19-JUL-1996 08:43:30.62

TO: Lee R. Johnson (JOHNSON_LR) (WHO)

READ:18-JUL-1996 16:02:34.06

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:18-JUL-1996 14:21:53.29

TO: Rosalyn A. Miller (MILLER_RA) (OPD)
READ:NOT READ

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:18-JUL-1996 15:34:46.10

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:18-JUL-1996 14:28:13.54

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:18-JUL-1996 15:04:32.02

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUL-1996 19:56:47.09

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:18-JUL-1996 14:55:14.00

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:18-JUL-1996 16:51:17.97

TO: Deborah L. Fine (FINE_D) (OPD)
READ:18-JUL-1996 18:17:52.07

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:18-JUL-1996 14:25:42.84

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:18-JUL-1996 17:31:34.25

TO: Pamela Cicetti (CICETTI_P) (WHO)
READ:22-JUL-1996 09:27:16.64

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 15:55:06.78

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:18-JUL-1996 15:34:15.57

TO: Thomas O'Donnell (O'DONNELL_T) (WHO)
READ:18-JUL-1996 17:37:00.49

TO: Gene B. Sperling (SPERLING_G) Autoforward to: Daniel Taberski (TABERSKI_D)
(WHO)
READ:18-JUL-1996 14:38:22.66

TO: Dan Tarullo (TARULLO_D) (OPD)
READ:18-JUL-1996 15:24:22.52

TO: Ellen S. Seidman (SEIDMAN_E) (OPD)
READ:19-JUL-1996 14:09:03.95

TO: Michael D. Deich (DEICH_M) (OPD)
READ:18-JUL-1996 14:29:45.96

TO: Paul R. Dimond (DIMOND_P) (OPD)
READ:NOT READ

TO: Dorothy Robyn (ROBYN_D) (OPD)
READ:18-JUL-1996 14:31:06.01

TO: Robert D. Kyle (KYLE_R) (OPD)
READ:NOT READ

TO: Melinda N. Bates (BATES_M) (WHO)
READ:18-JUL-1996 15:08:09.11

TO: Marc A. Hoberman (HOBERMAN_M) (WHO)
READ:18-JUL-1996 14:28:01.39

TO: Ann McCoy (MCCOY_A) (WHO)
READ:18-JUL-1996 17:16:36.53

TO: Rachel E. Levinson (LEVINSON_R) (STP)
READ:18-JUL-1996 14:40:06.90

TEXT:

This is a reminder that the farewell reception for Steve Neuwirth is from
4:00-5:30 today in the mess.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Diana M. Fortuna (FORTUNA_D) (OPD)

CREATION DATE/TIME:18-JUL-1996 17:55:44.82

SUBJECT: RE: DA&A

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:18-JUL-1996 18:12:41.83

CC: Molly Brostrom (BROSTROM_M) (WHO)

READ:18-JUL-1996 17:59:47.15

CC: Jeremy D. Benami (BENAMI_J) (WHO)

READ:18-JUL-1996 19:32:24.11

TEXT:

sounds good... but it would be good to get some ideas from the advocates on what more ssa could do.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 08:16:46.43

SUBJECT: fyi

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:24-JUL-1996 19:28:21.92

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 19:07:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jeremy D. Benami

ATT SUBJECT: erd email

ATT TO: Jeffrey Levi (LEVI_J)

TEXT:

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:17-JUL-1996 19:02:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Patricia M. McMahon

ATT SUBJECT: RE: AIDS Strategy

ATT TO: Jeremy D. Benami (BENAMI_J)

TEXT:

Thanks Jeremy

Barbara Roberts is working on it

Will check with her tomorrow

Ricia

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 18:17:32.96

SUBJECT: RE: DA&A

TO: Molly Brostrom (BROSTROM_M) (WHO)

READ:18-JUL-1996 18:29:48.44

CC: Diana M. Fortuna (FORTUNA_D) (OPD)

READ:19-JUL-1996 09:12:22.74

CC: Jeremy D. Benami (BENAMI_J) (WHO)

READ:18-JUL-1996 19:33:44.27

TEXT:

no need to wait for me...yes, someplace fun...our house in the mountains where beepers don't beep.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
--------------------------	---------------	------	-------------

001. email	From: Webwolf@teleport.com, To: Jeffrey Levi, Re: What Up? (2 pages)	07/18/1996	Personal Misfile
------------	--	------------	------------------

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 17:21:53.91

SUBJECT: DA&A

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:18-JUL-1996 17:55:48.44

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:18-JUL-1996 17:59:23.59

CC: Jeremy D. Benami (BENAMI_J) (WHO)
READ:18-JUL-1996 19:32:06.73

TEXT:

I received a call from Ellen Weber of the Legal Action Center expressing concerns about how the DA&A reapplication process is going. Apparently only a relatively small percentage of those notified have responded to date -- there is concern that without more outreach from SSA, there will be a lot of people pulled off the rolls who could have been kept on if they had been reached. Ellen is working with a group of disability folks in coming up with proposals about how this outreach could be improved. This might be a good time to: (1) meet with some of these folks to see how they think we are doing and (2) to get an update from SSA about how things are going and to see if there is any more we could prod them to do. This is easy for me to suggest, since I am going on vacation next week...but what do you think?
jeff

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 08:16:21.76

SUBJECT: fyi

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:24-JUL-1996 19:28:43.79

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-JUL-1996 19:05:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jeremy D. Benami

ATT SUBJECT: oops sent wrong email you'll figure this out

ATT TO: Jeffrey Levi (LEVI_J)

TEXT:

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:17-JUL-1996 18:58:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jeremy D. Benami

ATT SUBJECT: RE: AIDS Strategy

ATT TO: Patricia M. McMahon (MCMAHON_P)

TEXT:

Yes.

The AIDS Strategy MUST be at the printer on Monday. I realize that ONDCP may now have a problem with what Fred did previously, but it would be really great if whatever changes you need made could be given to the AIDS office ASAP or faster!! We are so late in getting this done, the deadlines can't slip any further!

Thanks.

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 17:49:06.56

SUBJECT: Tom Duane

TO: Richard Socarides (SOCARIDES_R) (WHO)

READ:19-JUL-1996 09:21:47.21

CC: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 15:55:44.39

TEXT:

I spoke with Tom about the three issues you mentioned to me:
on the NTZ shipment:

the person from the PWA Health Group screwed up: he failed to declare that he had these drugs; if he had declared (and he had prescriptions for them), the FDA is in charge and would have let them in. By failing to declare, this became a customs issue -- and there are now discussions with Customs (FDA has intervened) to try to release the drugs. I will call over to Treasury to see if this can be resolved faster.

on the Bureau of Prisons standard of care:

I explained that this is something we are working on; that Reno is interested in doing more on AIDS; that this is something we are going to propose. He is going to write Shalala and Reno -- since he mentioned this to Shalala in NYC and she seemed interested.

on the women in trials issue:

this is a Terry McGovern question -- about requiring inclusion of women in all clinical trials. I know there is an FDA reg in the works about women in HIV trials; but she wants this to go to all trials. I will speak to the person at FDA to see where things stand and to see if something more inclusive might also happen (Terry is planning to sue soon)

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:18-JUL-1996 17:00:00.00

SUBJECT: New Organizations 07/17/96

TO: levi_j (levi_j@A1@CD) (WHO)

READ:18-JUL-1996 17:05:11.07

TEXT:

CDC National AIDS Clearinghouse
Educational Materials Database

NEW ORGANIZATIONS
July 17, 1996

The Clearinghouse's Resources and Services Database contains organizational information about more than 18,000 organizations in the United States and around the world. Information includes organization name, address, phone numbers, a description of offered services, and the populations served.

NAC ONLINE users can search these databases by selecting "Clearinghouse Databases" from the NAC ONLINE main menu. When asked to enter a database name, specify "RDIR" (which stands for resources directory) to search all organizations.

To access the NAC ONLINE BBS, set your communications software to dial (800) 851-7245, and set the options for 8 data bits, N parity, 1 stopbit, full duplex, and complete a new user questionnaire. Only non-profit organizations, government agencies, educational institutions, and health departments are given full access to NAC ONLINE and the NAC databases.

Over the weekend, 12 newly catalogued organizations were loaded to the RDIR Resources and Services Database. This brings the total number of organizations on the Database to 18,722. The records follow.

AN S 32057

CN Center for Community Alternatives

AD 39 West 19th St., 3rd Floor

New York, NY 10011

PR (212) 691-1911

DE The Center for Community Alternatives runs two programs for parolees in New York. Choices I is for adolescents involved with the criminal justice system, and Choices II is for adult parolees. Prior to parole, discharge planning assistance is provided to facilitate the transition to life outside the prison system. AIDS education is an integral

part. HIV-positive Parolees are offered case management, counseling, and support groups.

AN S 32147

CN American Red Cross
AIDS Information Center

AD 167 Union St.
Concord, NC 28025-5011

PR (704) 782-9022

DE The AIDS Information Center is primarily a telephone information and referral service. AIDS educational materials are available also.

AN S 32641

CN Family Information and Referral Service Teams
Health Connection

AD 470 Mamaroneck Ave.
White Plains, NY 10605-1830

PR (914) 949-6789

PX (914) 948-1194

DE FIRST Health Connection facilitates access to health services in Westchester County by providing free and confidential referrals to them and information about them. An information specialist provides assistance in navigating the complex health care system, educates callers as to what questions to ask when looking for a special service, and directs callers to appropriate agencies when service was denied or inadequate. It also collaborates in the production of directories.

AN S 32643

CN Coastline Organization of Persons With AIDS

AD 2601 Ave. G
Galveston, TX 77550

PR (409) 762-0806

PE (800) 450-3445 - Nationwide.

PX (409) 762-2705

DE The Coastline Organization of Persons With AIDS (CO-PWA) provides peer counseling for persons living with or affected by HIV/AIDS. It operates a 24-hour national hotline for counseling, a drop-in center, a monthly newsletter, and support groups. It also provides referrals for other services.

AN S 32644

CN Triad Health Practice
HIV Treatment Clinic

AD 938 W. Nelson
Chicago, IL 60657

PR (312) 296-5732

PX (312) 296-8401

DE The Triad Health Practice/HIV Treatment Clinic provides medical and alternative therapies for HIV infection and other medical services. It also operates support groups for HIV-positive persons, conducts anonymous and confidential HIV-antibody testing and counseling, and provides referrals for other services.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:18-JUL-1996 17:00:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011784R9AQ8W0002ZW@PMDf.EOP.GOV> for levi_j@al.eop.gov; Thu, 18 Jul 1996 17:00:22 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <011784R2UPMI00007U@STORM.EOP.GOV> for levi_j@al.eop.gov; Thu, 18 Jul 1996 17:00:14 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id RAA13807; Thu, 18 Jul 1996 17:00:18 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:18-JUL-1996 13:16:00.00

SUBJECT: CDC AIDS Daily Summary 07/17/96

TO: levi_j (levi_j@A1@CD) (WHO)

READ:18-JUL-1996 15:38:52.74

TEXT:

AIDS Daily Summary
July 17, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

"Arbitrator's Ruling Could Cost J&J a Promising Unit"

"Across the USA: Kansas"

"Reform Isn't Risk-Free"

"Woman With HIV Charged in Sex Assault on Boy, 11"

"Group Provides Support, Structure for HIV Workers"

"P&U Says Working on More AIDS Drugs"

"Good Prenatal Care Linked to Positive Birth Outcomes in HIV-Infected Women"

"Executives Participating in Ride to Benefit AIDS"

"Olympic Potential"

"Health Care/Market Facts: AIDS Cases"

"Arbitrator's Ruling Could Cost J&J a Promising Unit"

Wall Street Journal (07/17/96) P. B4; Kuntz, Phil; McGinley, Laurie

As the result of an arbitrator's decision in an employment dispute, Johnson & Johnson (J&J) could lose control of Direct Access Diagnostics, the potentially profitable division that markets a home HIV test. Arbitrator John Gibbons said the company made illegal political donations to members of Congress and large contributions to a think tank affiliated with House Speaker Newt Gingrich in an effort to sway Food and Drug Administration (FDA) officials. The decision was part of a proceeding in which Gibbons ruled that J&J wrongly fired the test's developer, Elliott Millenson, for reasons related to publicity over the contributions. Millenson developed the test in 1985

and then sold his company to J&J when he could not get the test approved. Millenson's lawyer said that his client's employment contract calls for J&J to return his business to him, and pay him back salary and a \$1.5 million bonus because the FDA approved the test kit.

"Across the USA: Kansas"

USA Today (07/17/96) P. 10A

Due to limited funding, the Kansas AIDS Drug Assistance Program is no longer taking applications. Prospective applicants will be put on a waiting list.

"Reform Isn't Risk-Free"

Washington Post (07/17/96) P. A18

Legislation being considered in Congress to reform the Food and Drug Administration (FDA) should not be rushed, a Washington Post editorial asserts, urging advocates of reform to consider the potential risks to privatizing drug reviews. The editors note that the measures would make it easier for drug makers to advertise drugs as safe and effective for uses that have not been approved by the FDA. They also point out that pressure from AIDS activists has affected changes that have cut drug approval time in half since 1987, and that drugs given special priority have been approved in less than 6 months. In light of the extremely high stakes involved, the authors question whether Americans are ready to accept having the drug approval process shifted primarily to private hands, and conclude that any such change should be made only with caution and deliberation.

"Woman With HIV Charged in Sex Assault on Boy, 11"

Boston Globe (07/16/96) P. A6

A Florida woman with HIV was charged with second-degree murder and jailed after she had sex with an 11-year-old boy who played baseball with her son. The original charge against the woman, Stacey Renee Jacobs, 32, was for sexual battery on a child under age 12. After tests showed that Jacobs was HIV-positive, she was also charged with attempted murder. The child is being tested for the virus.

"Group Provides Support, Structure for HIV Workers"

Boston Globe (07/16/96) P. D12; Brudney, Juliet F.

Changing Directions, a support group for people who leave work because of AIDS, provides a forum for dealing with the emotional and practical aspects of a problem most AIDS patients eventually face. The group, associated with the AIDS Action Committee of Massachusetts, was founded by Matthew Feldman to help members learn about sources of financial support. Members learn from each other's experiences and help each other cope with similar problems.

"P&U Says Working on More AIDS Drugs"

Reuters (07/17/96)

Pharmacia & Upjohn announced Wednesday that it is developing other new AIDS drugs in addition to Rescriptor, a drug for which

it is currently seeking Food and Drug Administration approval. Rescriptor has been tested in more than 2,600 AIDS patients, and company spokesman Soren Densjo said it appears to stop the disease from progressing.

"Good Prenatal Care Linked to Positive Birth Outcomes in HIV-Infected Women"

Reuters (07/16/96)

With adequate prenatal care, adverse birth outcomes can be cut in half for children born to women infected with HIV, researchers at the Jefferson Medical College in Philadelphia report. Barbara J. Turner and colleagues reviewed New York State Medicaid records of more than 2,200 HIV-infected women who gave birth between 1985 and 1990. The researchers report that the odds of low birth weight and preterm birth for women with adequate prenatal care were 48 percent and 21 percent lower, respectively, than for those individuals who had inadequate prenatal care.

"Executives Participating in Ride to Benefit AIDS"

Journal of Commerce (07/17/96) P. 4B

Two New York transportation executives will participate in the 3-day, 300-mile Boston-to-New York AIDS Ride fundraiser. Thomas Dierson of Polar Steamship Line and Buck Broker of Lufthansa German Airlines will be among the 4,000 riders raising money in September for people with AIDS in the two cities.

"Olympic Potential"

Advocate (07/09/96) No. 711; P. 27; Allan, Christina

The issue of HIV-positive athletes competing in Olympic events was highlighted by gold medalist Greg Louganis' revelation last year that he is HIV-positive. While HIV awareness has improved, HIV and gay stigmas persist in the Olympic community. Moreover, two Olympic-affiliated associations continue to bar HIV-positive athletes from their competitions, and the Immigration and Naturalization Service requires HIV-positive Olympic athletes and visitors to have special permission to enter the country. The Centers for Disease Control and Prevention (CDC), however, says there is no public health basis for routinely testing athletes for HIV or excluding them from sports because of their HIV status. But two amateur sports organizations, USA Boxing and USA Wrestling, prohibit HIV-positive athletes from competing, and both belong to the United States Olympic Committee (USOC) and receive funding from it. Although neither group requires athletes to take an HIV test, USA Boxing recommends yearly tests for its members. The USOC does not have any regulations regarding HIV and does not require disclosure or testing.

"Health Care/Market Facts: AIDS Cases"

Crain's Cleveland Business

Vol. 17, No. 27 (07/01/96) P. M-8

In Ohio, there have been a total of 2,599 AIDS cases documented since 1981, with 1,575 deaths attributed to the disease. The state recorded 350 AIDS cases in 1994, 273 of which

were in Cuyahoga County. The number of newly diagnosed cases decreased to 245 in 1995, with 199 in Cuyahoga County. As of March 1996, there were 29 AIDS cases reported in the state, with the majority once again located in Cuyahoga.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:18-JUL-1996 13:16:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01177WX7744G0010FD@PMDF.EOP.GOV> for
levi_j@al.eop.gov; Thu, 18 Jul 1996 13:16:06 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01177WWZ8Z7400007U@STORM.EOP.GOV> for
levi_j@al.eop.gov; Thu, 18 Jul 1996 13:15:56 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id NAA29492; Thu,
18 Jul 1996 13:16:01 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Molly Brostrom (BROSTROM_M) (WHO)

CREATION DATE/TIME:18-JUL-1996 18:09:56.10

SUBJECT: RE: DA&A

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:18-JUL-1996 18:12:59.66

CC: Diana M. Fortuna (FORTUNA_D) (OPD)

READ:19-JUL-1996 09:12:12.87

CC: Jeremy D. Benami (BENAMI_J) (WHO)

READ:18-JUL-1996 19:32:35.16

TEXT:

Diana -- should you and I try to meet with the advocates next week? setting something up with Ellen and letting her decide if/whom else to bring? or do either of you think we need to wait 'til Jeff's back?
(going any place fun, Jeff?)

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
002. email	From: Jeffrey Levi, To: Webwolf@teleport.com, Re: What Up? (1 page)	07/18/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 17:56:42.24

SUBJECT: RE: DA&A

TO: Diana M. Fortuna (FORTUNA_D) (OPD)

READ:19-JUL-1996 09:12:08.47

CC: Molly Brostrom (BROSTROM_M) (WHO)

READ:18-JUL-1996 17:59:52.13

CC: Jeremy D. Benami (BENAMI_J) (WHO)

READ:18-JUL-1996 19:32:29.86

TEXT:

i agree...we should try to meet with the advocates first. how
should we proceed?

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME: 18-JUL-1996 10:21:00.00

SUBJECT: CDC AIDS Daily Summary 07/18/96

TO: levi_j (levi_j@A1@CD) (WHO)

READ: 18-JUL-1996 15:38:07.75

TEXT:

AIDS Daily Summary
July 18, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

"Buyer of AIDS Patients' Insurance Quitting"

"Tiny Czech Lab Makes Promising Gains With Drugs for AIDS, Related Illness"

"BioChem Shares Tumble in Nasdaq Carnage, Despite Drug's Critical Role in AIDS Cocktail"

"Preventing AIDS Is Still the Best Investment"

"AIDS Protesters Confront Chretien"

"Attorney Honored for Giving Free Assistance to HIV-Positive Clients"

"Shortsighted Prescription-Drug Policy"

"Mother Breast Feeds HIV Baby"

"Health Care/Market Facts: Tracking AIDS Is Tricky Business"

"Buyer of AIDS Patients' Insurance Quitting"

New York Times (07/18/96) P. D8

Dignity Partners, one of the first companies to buy life insurance policies from AIDS patients, announced a halt to its business on Wednesday. The company noted that new drugs that prolong survival of people with AIDS may hurt their business. The company's share price on the Nasdaq stock market dropped 77 percent to \$1.375 on the news, down \$4.6875. More than 95 percent of Dignity Partners' business involved policies held by people with HIV or AIDS, the company said.

"Tiny Czech Lab Makes Promising Gains With Drugs for AIDS, Related Illness"

Wall Street Journal (07/18/96) P. A6; Calbreath, Dean

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences has developed a drug for AIDS-related blindness that recently hit the market. Analysts predict that the drug Vistide, licensed to Gilead Sciences of Foster City, Calif., could bring in \$45 million in annual sales. The institute has also developed two anti-HIV drugs--PMPA, which could replace Glaxo Wellcome's AZT, and PMEA, which Gilead is already readying for marketing. PMPA, which may be able to prevent HIV infection, has an advantage over AZT in that it does not need to be absorbed by the body's cells to begin blocking HIV.

"BioChem Shares Tumble in Nasdaq Carnage, Despite Drug's Critical Role in AIDS Cocktail"

Wall Street Journal (07/18/96) P. C2; McGough, Robert; Chipello, Christopher J.

BioChem Pharma was not spared in the recent carnage in the Nasdaq Stock Market, even though its AIDS drug 3TC was reported to be a critical factor in AIDS treatment. Last week, the company's stock closed 43 percent below its May peak of 50. In the past two days, however, the stock has rebounded, closing Wednesday up 1, at 32. 3TC, which is manufactured and sold outside of Canada by Glaxo Wellcome, is part of a three-drug combination that appears to be able to suppress HIV.

"Preventing AIDS Is Still the Best Investment"

New York Times (07/18/96) P. A22; Lamptey, Peter; Gelman, Irwin H.; Duane, Thomas K.

In a series of letters to the editor appearing in the New York Times, three writers take issue with various points made in Gabriel Rotello's July 14 commentary. Dr. Peter Lamptey, director of the AIDS Control and Prevention Project, argues that AIDS prevention efforts have not failed, as Rotello suggests. Lamptey cites increased condom use and reductions in HIV infection rates. Meanwhile, Irwin H. Gelman, a microbiologist at the Mount Sinai School of Medicine, writes that, without an effective vaccine, combination drug therapies are the best hope for treating HIV infection. Furthermore, Thomas K. Duane, a member of the New York City Council, objects to Rotello's proposal to exclude patients from drug therapy programs based on their inability to follow a strict regimen.

"AIDS Protesters Confront Chretien"

Toronto Globe and Mail (07/17/96) P. A4; Cox, Kevin

At a campaign-style picnic on Tuesday, Canadian Prime Minister Jean Chretien was met by AIDS activists who complained that Chretien had not attended the international AIDS conference in Vancouver last week. Chretien, who said he was on vacation with his family, pointed out that the Canadian government has spent \$41 million a year on a five-year plan to combat the disease. He accused some activists of falsely claiming that support for AIDS research is being cut off next year.

"Attorney Honored for Giving Free Assistance to HIV-Positive

Clients"

Houston Chronicle (07/17/96) P. 22A; Villafranca, Armando

Houston attorney Michael Katine has been honored by the State Bar of Texas with the 1996 Frank J. Scurlock award for providing free legal services to HIV-positive indigent clients. Katine took on HIV-positive clients in the early- and mid-1980s, despite the jeers and jibes from some of his peers and the strong social stigma against people with the virus. For two years, Katine has held free legal workshops and seminars on HIV and the law. He volunteers as legal counsel for both the Montrose Clinic and the Loving Arms Foundation, which provide free medical care to HIV patients. Katine continues to serve the HIV-community, providing estate planning, dealing with insurance conflicts, and job discrimination.

"Shortsighted Prescription-Drug Policy"

Washington Post (07/18/96) P. A26; Gibson, Thomas F.

In a letter to the editor of the Washington Post, Thomas Gibson, president of the American Lung Association, responds to a Post series on TennCare, contending that the program may hurt efforts to combat tuberculosis (TB). TennCare's prescription drug program covers only partial TB therapy, Gibson says, which could result in the emergence of drug-resistant strains. He points out that the program is too restrictive of doctors' abilities to prescribe drugs, denying them the authority to use their best judgment. In the case of TB, he says that patients would not be able to get the most effective drugs until they are hospitalized.

"Mother Breast Feeds HIV Baby"

United Press International (07/16/96)

A woman who accidentally breast fed a baby born to an HIV-positive mother said Tuesday that she will sue the hospital if it does not settle out of court for \$200,000. The mother and her own child have not tested positive for the virus, but a six-month detection period is needed to be sure they are not infected. The woman had been given the wrong baby to nurse by a staffer at Broward Medical Center. Hospital officials said there is only a small chance the baby could give the woman HIV and claimed there was no grounds for a settlement because no one was hurt.

"Health Care/Market Facts: Tracking AIDS Is Tricky Business"

Crain's Chicago Business (07/01/96) Vol. 19, No. 27, P. F12;

Ferkenhoff, Eric

Health care experts warn that the reported 30 percent decline in the number of AIDS cases in Chicago between 1994 and 1995 could be misleading. The number of cases reported reflects how many are processed by surveillance officials during the year, not necessarily the number of cases diagnosed, they note. James Cappleman, a social worker with the AIDS program at St. Joseph's Health Center and Hospital, said the number of cases is not declining, but may be holding steady. The figures may be misleading due to previously overlooked cases being tracked down later and added to totals for later years. Overstating the gains made is dangerous because "people who don't even acknowledge the

fact that they're at risk are now going to start thinking the epidemic is going away," says James Murphy, of the Chicago Department of Public Health.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:18-JUL-1996 10:24:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I77QTUB374000X92@PMDF.EOP.GOV> for levi_j@al.eop.gov; Thu, 18 Jul 1996 10:21:35 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I77QTJXVN200007U@STORM.EOP.GOV> for levi_j@al.eop.gov; Thu, 18 Jul 1996 10:21:27 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA14694; Thu, 18 Jul 1996 10:21:25 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 11:52:11.63

SUBJECT: a few other things

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:18-JUL-1996 12:29:44.09

TEXT:

Patsy won't be in today or tomorrow -- she asked to let you know that she must cancel lunch.

Can you call Kevin Thurm -- he and Patsy have not connected -- and see if we can set something up -- maybe this afternoon or tomorrow, even a conference call -- to work out the "philosophical" issues the department seems to have with the strategy. We have received -- and will be incorporating -- their technical comments. But we have yet to have communicated to us this larger issue...so we are flying blind.

For your information -- and we have told no agencies this -- we don't have to go to the printer on Monday to make our August 8th release date. We do want to be done by Monday -- so we can do one more very careful review internally before it gets formatted for printing midweek.

Thanks for all you are doing on this.

I will be out of the office till three -- you can page me.

Also--

I faxed the revised scheduling request to Steve Silverman.

If there is word about a radio speech...let Richard know so he can start on things.

Pray that all this gets resolved, I plan to be on vacation -- though reachable -- next week.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:18-JUL-1996 18:43:18.77

SUBJECT: Materials for Communications/Press

TO: Elizabeth E. Drye (DRYE_E) (OPD)
READ:18-JUL-1996 18:55:02.13

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:18-JUL-1996 19:36:12.63

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:18-JUL-1996 18:43:34.01

TO: Dennis Burke (BURKE_D) (OPD)
READ:24-JUL-1996 07:54:33.17

TO: Diane Regas (REGAS_D) (OPD)
READ:18-JUL-1996 18:52:38.60

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 15:56:41.30

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:19-JUL-1996 09:13:29.11

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:19-JUL-1996 08:21:42.58

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUL-1996 20:02:55.26

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:18-JUL-1996 18:43:41.87

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:18-JUL-1996 18:44:24.51

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:18-JUL-1996 21:14:40.84

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:19-JUL-1996 10:16:47.33

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:18-JUL-1996 20:55:53.09

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:19-JUL-1996 09:11:59.50

TO: Michael Cohen (COHEN_M) (OPD)
READ:19-JUL-1996 15:14:53.04

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:19-JUL-1996 16:44:35.11

TEXT:

If you prepare talking points, Q&A, or other materials for McCurry's and Baer's office please remember to put a copy in Carol's mail or cc her by e-mail. She doesn't necessarily need to see in advance, but should see concurrently.

Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 08:19:09.00

SUBJECT: RE: Use of ITR on Aug. 12

TO: Kim Holmes (HOLMES_K) (WHO)

READ:18-JUL-1996 09:09:21.64

TEXT:

thanks...who at counsel's office should review the invite? who do I have the AIDS fund talk to about other logistics (I'm new at this) -- i.e., catering -- and does the AIDS office to the clearing in of guests -- and do I need to make special arrangements with the Secret Service for that afternoon? thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 15:39:48.90

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 16:26:23.17

TO: Ursula Sanville (SANVILLE_U) (OPD)
READ:NOT READ

TO: Lahoma Romocki (ROMOCKI_L) (OPD)
READ:19-JUL-1996 14:19:46.01

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:18-JUL-1996 13:16:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 07/17/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
July 17, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

"Arbitrator's Ruling Could Cost J&J a Promising Unit"

"Across the USA: Kansas"

"Reform Isn't Risk-Free"

"Woman With HIV Charged in Sex Assault on Boy, 11"

"Group Provides Support, Structure for HIV Workers"

"P&U Says Working on More AIDS Drugs"

"Good Prenatal Care Linked to Positive Birth Outcomes in HIV-Infected Women"

"Executives Participating in Ride to Benefit AIDS"

"Olympic Potential"

"Health Care/Market Facts: AIDS Cases"

"Arbitrator's Ruling Could Cost J&J a Promising Unit"

Wall Street Journal (07/17/96) P. B4; Kuntz, Phil; McGinley, Laurie

As the result of an arbitrator's decision in an employment dispute, Johnson & Johnson (J&J) could lose control of Direct Access Diagnostics, the potentially profitable division that markets a home HIV test. Arbitrator John Gibbons said the company made illegal political donations to members of Congress and large contributions to a think tank affiliated with House Speaker Newt Gingrich in an effort to sway Food and Drug Administration (FDA) officials. The decision was part of a proceeding in which Gibbons ruled that J&J wrongly fired the test's developer, Elliott Millenson, for reasons related to publicity over the contributions. Millenson developed the test in 1985 and then sold his company to J&J when he could not get the test approved. Millenson's lawyer said that his client's employment contract calls for J&J to return his business to him, and pay him back salary and a \$1.5 million bonus because the FDA approved the test kit.

"Across the USA: Kansas"

USA Today (07/17/96) P. 10A

Due to limited funding, the Kansas AIDS Drug Assistance Program is no longer taking applications. Prospective applicants will be put on a waiting list.

"Reform Isn't Risk-Free"

Washington Post (07/17/96) P. A18

Legislation being considered in Congress to reform the Food and Drug Administration (FDA) should not be rushed, a Washington Post editorial asserts, urging advocates of reform to consider the potential risks to privatizing drug reviews. The editors note that the measures would make it easier for drug makers to advertise drugs as safe and effective for uses that have not been approved by the FDA. They also point out that pressure from AIDS activists has affected changes that have cut drug approval time in half since 1987, and that drugs given special priority have been approved in less than 6 months. In light of the extremely high stakes involved, the authors question whether Americans are ready to accept having the drug approval process shifted primarily to private hands, and conclude that any such change should be made only with caution and deliberation.

"Woman With HIV Charged in Sex Assault on Boy, 11"

Boston Globe (07/16/96) P. A6

A Florida woman with HIV was charged with second-degree murder and jailed after she had sex with an 11-year-old boy who played baseball with her son. The original charge against the woman, Stacey Renee Jacobs, 32, was for sexual battery on a child under

age 12. After tests showed that Jacobs was HIV-positive, she was also charged with attempted murder. The child is being tested for the virus.

"Group Provides Support, Structure for HIV Workers"

Boston Globe (07/16/96) P. D12; Brudney, Juliet F.

Changing Directions, a support group for people who leave work because of AIDS, provides a forum for dealing with the emotional and practical aspects of a problem most AIDS patients eventually face. The group, associated with the AIDS Action Committee of Massachusetts, was founded by Matthew Feldman to help members learn about sources of financial support. Members learn from each other's experiences and help each other cope with similar problems.

"P&U Says Working on More AIDS Drugs"

Reuters (07/17/96)

Pharmacia & Upjohn announced Wednesday that it is developing other new AIDS drugs in addition to Rescriptor, a drug for which it is currently seeking Food and Drug Administration approval. Rescriptor has been tested in more than 2,600 AIDS patients, and company spokesman Soren Densjo said it appears to stop the disease from progressing.

"Good Prenatal Care Linked to Positive Birth Outcomes in HIV-Infected Women"

Reuters (07/16/96)

With adequate prenatal care, adverse birth outcomes can be cut in half for children born to women infected with HIV, researchers at the Jefferson Medical College in Philadelphia report. Barbara J. Turner and colleagues reviewed New York State Medicaid records of more than 2,200 HIV-infected women who gave birth between 1985 and 1990. The researchers report that the odds of low birth weight and preterm birth for women with adequate prenatal care were 48 percent and 21 percent lower, respectively, than for those individuals who had inadequate prenatal care.

"Executives Participating in Ride to Benefit AIDS"

Journal of Commerce (07/17/96) P. 4B

Two New York transportation executives will participate in the 3-day, 300-mile Boston-to-New York AIDS Ride fundraiser. Thomas Dierson of Polar Steamship Line and Buck Broker of Lufthansa German Airlines will be among the 4,000 riders raising money in September for people with AIDS in the two cities.

"Olympic Potential"

Advocate (07/09/96) No. 711; P. 27; Allan, Christina

The issue of HIV-positive athletes competing in Olympic events was highlighted by gold medalist Greg Louganis' revelation last year that he is HIV-positive. While HIV awareness has improved, HIV and gay stigmas persist in the Olympic community. Moreover, two Olympic-affiliated associations continue to bar HIV-positive athletes from their competitions, and the Immigration and

Naturalization Service requires HIV-positive Olympic athletes and visitors to have special permission to enter the country. The Centers for Disease Control and Prevention (CDC), however, says there is no public health basis for routinely testing athletes for HIV or excluding them from sports because of their HIV status. But two amateur sports organizations, USA Boxing and USA Wrestling, prohibit HIV-positive athletes from competing, and both belong to the United States Olympic Committee (USOC) and receive funding from it. Although neither group requires athletes to take an HIV test, USA Boxing recommends yearly tests for its members. The USOC does not have any regulations regarding HIV and does not require disclosure or testing.

"Health Care/Market Facts: AIDS Cases"

Crain's Cleveland Business

Vol. 17, No. 27 (07/01/96) P. M-8

In Ohio, there have been a total of 2,599 AIDS cases documented since 1981, with 1,575 deaths attributed to the disease. The state recorded 350 AIDS cases in 1994, 273 of which were in Cuyahoga County. The number of newly diagnosed cases decreased to 245 in 1995, with 199 in Cuyahoga County. As of March 1996, there were 29 AIDS cases reported in the state, with the majority once again located in Cuyahoga.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:18-JUL-1996 13:16:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01177WX7744G0010FD@PMDf.EOP.GOV> for levi_j@al.eop.gov; Thu, 18 Jul 1996 13:16:06 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01177WWZ8Z7400007U@STORM.EOP.GOV> for levi_j@al.eop.gov; Thu, 18 Jul 1996 13:15:56 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id NAA29492; Thu, 18 Jul 1996 13:16:01 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:18-JUL-1996 15:38:45.15

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 16:27:08.55

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:NOT READ

TO: Lahoma Romocki (ROMOCKI_L) (OPD)

READ:19-JUL-1996 14:06:31.74

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:18-JUL-1996 10:21:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 07/18/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
July 18, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

"Buyer of AIDS Patients' Insurance Quitting"

"Tiny Czech Lab Makes Promising Gains With Drugs for AIDS, Related Illness"

"BioChem Shares Tumble in Nasdaq Carnage, Despite Drug's Critical Role in AIDS Cocktail"

"Preventing AIDS Is Still the Best Investment"

"AIDS Protesters Confront Chretien"

"Attorney Honored for Giving Free Assistance to HIV-Positive

Clients"

"Shortsighted Prescription-Drug Policy"

"Mother Breast Feeds HIV Baby"

"Health Care/Market Facts: Tracking AIDS Is Tricky Business"

"Buyer of AIDS Patients' Insurance Quitting"

New York Times (07/18/96) P. D8

Dignity Partners, one of the first companies to buy life insurance policies from AIDS patients, announced a halt to its business on Wednesday. The company noted that new drugs that prolong survival of people with AIDS may hurt their business. The company's share price on the Nasdaq stock market dropped 77 percent to \$1.375 on the news, down \$4.6875. More than 95 percent of Dignity Partners' business involved policies held by people with HIV or AIDS, the company said.

"Tiny Czech Lab Makes Promising Gains With Drugs for AIDS, Related Illness"

Wall Street Journal (07/18/96) P. A6; Calbreath, Dean

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences has developed a drug for AIDS-related blindness that recently hit the market. Analysts predict that the drug Vistide, licensed to Gilead Sciences of Foster City, Calif., could bring in \$45 million in annual sales. The institute has also developed two anti-HIV drugs--PMPA, which could replace Glaxo Wellcome's AZT, and PMEA, which Gilead is already readying for marketing. PMPA, which may be able to prevent HIV infection, has an advantage over AZT in that it does not need to be absorbed by the body's cells to begin blocking HIV.

"BioChem Shares Tumble in Nasdaq Carnage, Despite Drug's Critical Role in AIDS Cocktail"

Wall Street Journal (07/18/96) P. C2; McGough, Robert; Chipello, Christopher J.

BioChem Pharma was not spared in the recent carnage in the Nasdaq Stock Market, even though its AIDS drug 3TC was reported to be a critical factor in AIDS treatment. Last week, the company's stock closed 43 percent below its May peak of 50. In the past two days, however, the stock has rebounded, closing Wednesday up 1, at 32. 3TC, which is manufactured and sold outside of Canada by Glaxo Wellcome, is part of a three-drug combination that appears to be able to suppress HIV.

"Preventing AIDS Is Still the Best Investment"

New York Times (07/18/96) P. A22; Lamptey, Peter; Gelman, Irwin H.; Duane, Thomas K.

In a series of letters to the editor appearing in the New York Times, three writers take issue with various points made in Gabriel Rotello's July 14 commentary. Dr. Peter Lamptey, director of the AIDS Control and Prevention Project, argues that AIDS prevention efforts have not failed, as Rotello suggests. Lamptey cites increased condom use and reductions in HIV infection rates. Meanwhile, Irwin H. Gelman, a microbiologist at

the Mount Sinai School of Medicine, writes that, without an effective vaccine, combination drug therapies are the best hope for treating HIV infection. Furthermore, Thomas K. Duane, a member of the New York City Council, objects to Rotello's proposal to exclude patients from drug therapy programs based on their inability to follow a strict regimen.

"AIDS Protesters Confront Chretien"

Toronto Globe and Mail (07/17/96) P. A4; Cox, Kevin

At a campaign-style picnic on Tuesday, Canadian Prime Minister Jean Chretien was met by AIDS activists who complained that Chretien had not attended the international AIDS conference in Vancouver last week. Chretien, who said he was on vacation with his family, pointed out that the Canadian government has spent \$41 million a year on a five-year plan to combat the disease. He accused some activists of falsely claiming that support for AIDS research is being cut off next year.

"Attorney Honored for Giving Free Assistance to HIV-Positive Clients"

Houston Chronicle (07/17/96) P. 22A; Villafranca, Armando

Houston attorney Michael Katine has been honored by the State Bar of Texas with the 1996 Frank J. Scurlock award for providing free legal services to HIV-positive indigent clients. Katine took on HIV-positive clients in the early- and mid-1980s, despite the jeers and jibes from some of his peers and the strong social stigma against people with the virus. For two years, Katine has held free legal workshops and seminars on HIV and the law. He volunteers as legal counsel for both the Montrose Clinic and the Loving Arms Foundation, which provide free medical care to HIV patients. Katine continues to serve the HIV-community, providing estate planning, dealing with insurance conflicts, and job discrimination.

"Shortsighted Prescription-Drug Policy"

Washington Post (07/18/96) P. A26; Gibson, Thomas F.

In a letter to the editor of the Washington Post, Thomas Gibson, president of the American Lung Association, responds to a Post series on TennCare, contending that the program may hurt efforts to combat tuberculosis (TB). TennCare's prescription drug program covers only partial TB therapy, Gibson says, which could result in the emergence of drug-resistant strains. He points out that the program is too restrictive of doctors' abilities to prescribe drugs, denying them the authority to use their best judgment. In the case of TB, he says that patients would not be able to get the most effective drugs until they are hospitalized.

"Mother Breast Feeds HIV Baby"

United Press International (07/16/96)

A woman who accidentally breast fed a baby born to an HIV-positive mother said Tuesday that she will sue the hospital if it does not settle out of court for \$200,000. The mother and her own child have not tested positive for the virus, but a six-month detection period is needed to be sure they are not infected. The

woman had been given the wrong baby to nurse by a staffer at Broward Medical Center. Hospital officials said there is only a small chance the baby could give the woman HIV and claimed there was no grounds for a settlement because no one was hurt.

"Health Care/Market Facts: Tracking AIDS Is Tricky Business"
Crain's Chicago Business (07/01/96) Vol. 19, No. 27, P. F12;
Ferkenhoff, Eric

Health care experts warn that the reported 30 percent decline in the number of AIDS cases in Chicago between 1994 and 1995 could be misleading. The number of cases reported reflects how many are processed by surveillance officials during the year, not necessarily the number of cases diagnosed, they note. James Cappleman, a social worker with the AIDS program at St. Joseph's Health Center and Hospital, said the number of cases is not declining, but may be holding steady. The figures may be misleading due to previously overlooked cases being tracked down later and added to totals for later years. Overstating the gains made is dangerous because "people who don't even acknowledge the fact that they're at risk are now going to start thinking the epidemic is going away," says James Murphy, of the Chicago Department of Public Health.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:18-JUL-1996 10:24:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01177QTUB374000X92@PMDf.EOP.GOV> for
levi_j@al.eop.gov; Thu, 18 Jul 1996 10:21:35 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01177QTJXVN200007U@STORM.EOP.GOV> for
levi_j@al.eop.gov; Thu, 18 Jul 1996 10:21:27 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA14694; Thu,
18 Jul 1996 10:21:25 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye (DRYE_E) (OPD)

CREATION DATE/TIME:18-JUL-1996 15:16:53.29

SUBJECT: Computer inventory

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:18-JUL-1996 19:26:45.46

TO: Janet B. Abrams (ABRAMS_J) (VPO)
READ:21-JUL-1996 10:07:27.70

TO: Molly Brostrom (BROSTROM_M) (WHO)
READ:18-JUL-1996 15:20:06.23

TO: Sandra L. Bublick-Max (BUBLICKMAX_S) (OPD)
READ:19-JUL-1996 16:43:59.31

TO: Dennis Burke (BURKE_D) (OPD)
READ:24-JUL-1996 07:54:19.35

TO: Michael Cohen (COHEN_M) (OPD)
READ:18-JUL-1996 15:18:27.52

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:18-JUL-1996 15:37:49.20

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 15:55:23.65

TO: Diana M. Fortuna (FORTUNA_D) (OPD)
READ:18-JUL-1996 15:45:02.26

TO: Lyndell Hogan (HOGAN_L) (OPD)
READ:18-JUL-1996 18:28:28.88

TO: Christopher C. Jennings (JENNINGS_C) (WHO)
READ:19-JUL-1996 08:20:27.54

TO: Dorothy L. Karayannis (KARAYANNIS_D)
READ:NOT READ

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:18-JUL-1996 19:57:08.30

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:18-JUL-1996 15:34:24.10

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:18-JUL-1996 15:28:31.72

TO: Rosalyn A. Miller (MILLER_RA) (OPD)
READ:NOT READ

TO: Bruce N. Reed (REED_B) (WHO)
READ:18-JUL-1996 18:22:04.62

TO: Diane Regas (REGAS_D) (OPD)
READ:18-JUL-1996 17:20:01.79

TO: Denise Ricketson (RICKETSON_D) (OPD)
READ:18-JUL-1996 15:38:55.53

TO: Jeanine D. Smartt (SMARTT_J) (OPD)
READ:18-JUL-1996 15:27:09.30

TO: Stephen C. Warnath (WARNATH_S) (OPD)
READ:18-JUL-1996 17:31:45.52

TO: Paul J. Weinstein, Jr (WEINSTEIN_P) (OPD)
READ:18-JUL-1996 15:20:32.45

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:18-JUL-1996 15:18:58.61

TEXT:

Two of our interns -- Manoj Mate and Bridgette Carberry -- will be coming by your office this afternoon to measure the hard drive and buffer space on your computer. The process will take 3-4 minutes. We're doing this inventory now to prepare for purchasing decisions we will need to make in the next couple of weeks. Thanks. Sorry for the short notice.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:06:52.60

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 16:10:48.26

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:NOT READ

TO: Lahoma Romocki (ROMOCKI_L) (OPD)

READ:NOT READ

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-JUL-1996 11:03:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 07/19/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
July 19, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

"Merck's Sales Boosted Net 13% in Quarter"

"Firm Wilts on Positive News on AIDS Fight"

"Some With AIDS May Be Told to Shun Measles Vaccine"

"Asian Members Seek "Functional Cooperation" "

"American Lung Association Calls for Global Effort to Control TB"

"Scientist Calls for New Process to Accelerate Progress Toward an AIDS Vaccine"

"Rifabutin Shows Efficacy in Treatment of AIDS-Related M. avium

Infection"

"Microsporidia Linked to Malabsorption and Wasting in AIDS Patients"

"NAC: First Controlled Trial, Positive Results"

"Court Rules That Tainted-Blood Commissioner Can Investigate Misconduct"

"Merck's Sales Boosted Net 13% in Quarter"

Wall Street Journal (07/19/96) P. B3; Naj, Amal Kumar

Strong sales of several Merck products, including its new AIDS drug Crixivan, helped boost the company's second-quarter profit 13 percent to \$972.1 million. Sales for the quarter increased 19 percent to \$4.91 billion, meeting Wall Street analysts' projections. Crixivan, Merck's new protease inhibitor, has already been prescribed for 30,000 patients since it became available two months ago and has generated \$27 million in sales. The company also reported strong sales for its Varivax chicken pox vaccine; Fosamax, an osteoporosis drug; and two cholesterol-lowering drugs, Mevacor and Zocor.

"Firm Wilts on Positive News on AIDS Fight"

Houston Chronicle (07/18/96) P. 2C

Shares of the viatical settlement company Dignity Partners fell 77 percent after it announced late Tuesday that it would no longer buy life insurance policies from AIDS patients due to advances in treating the disease. The San Francisco business was the first public company to specialize in viatical settlements, and more than 95 percent of its customers were people with HIV or AIDS. The company said that progress in AIDS treatment presented at the XIth International Conference on AIDS last week could hurt its profits, which depend on being able to assess how long a person will live.

"Some With AIDS May Be Told to Shun Measles Vaccine"

Reuters (07/18/96)

Officials at the Centers for Disease Control and Prevention (CDC) said Thursday that they were considering telling some people with AIDS to avoid getting measles vaccinations. The concern arose after it was discovered that a 20-year-old man whose immune system was weakened by HIV died from pneumonitis caused by the measles virus. The man did not become ill until a year after he received the vaccine, and the cause of his illness was not discovered until last year, though he died in 1993. The CDC reported that this was the first known case of a serious complication from measles vaccination in an HIV-infected person with severely weakened immunity. The agency said that, for now, HIV-infected individuals who are not severely immunocompromised should continue to receive the combination measles-mumps-rubella vaccine.

"Asian Members Seek 'Functional Cooperation' "

Journal of Commerce (07/19/96) P. 4A

Countries in Southeast Asia plan to improve cooperation in

such programs as scientific development and AIDS prevention and control, Indonesian Foreign Minister Ali Alatas said Thursday. Alatas said that the standing committee of the Association of Southeast Asian Nations would call for Asian foreign ministers to adopt a framework to give "functional cooperation" between member states a higher priority.

"American Lung Association Calls for Global Effort to Control TB"
Reuters (07/18/96)

Global cooperation is needed to prevent and control the spread of tuberculosis (TB), delegates to the American Lung Association Conference on Re-establishing Control of Tuberculosis in the United States reported. The group said that health departments should have greater legal authority to monitor and control TB, including the detention of unmanageable patients. Other recommendations included improved communication between TB and HIV treatment programs, and development of a new TB vaccine. Meeting notes were published in the July issue of the American Journal of Respiratory and Critical Care Medicine.

"Scientist Calls for New Process to Accelerate Progress Toward an AIDS Vaccine"
Reuters (07/18/96)

Richard T. Mahoney of the International Vaccine Institute in Seoul, South Korea, asserts that current AIDS vaccine development efforts are insufficient and that a comprehensive management system is necessary to yield results. In a commentary in the Spring issue of the AIDS and Public Policy Journal, he writes that current research should receive greater funding and that the "most appropriate system to accelerate development of an HIV vaccine is the consultative-group model." Currently, about \$25 million is being spent each year on vaccine development, but Mahoney says that some \$200 million to \$300 million a year will have to be invested to produce a single new vaccine.

"Rifabutin Shows Efficacy in Treatment of AIDS-Related M. avium Infection"
Reuters (07/18/96)

French researchers report that rifabutin is active against Mycobacterium avium alone and makes a significant contribution to combination therapy for the treatment of disseminated M. avium infection in AIDS patients. Dr. Bertrand Dautzenberg et al. at the Groupe Hospitalier Pitie-Salpetriere in Paris report their findings in the July issue of Antimicrobial Agents and Chemotherapy. Their study of 10 AIDS patients with M. avium infection found that rifabutin was effective after two weeks in seven of the individuals.

"Microsporidia Linked to Malabsorption and Wasting in AIDS Patients"
Reuters (07/18/96)

Microsporidia infection is related to malabsorption and malnutrition in AIDS patients with chronic diarrhea, say researchers at the New England Deaconess Hospital. Christine A.

Wanke and colleagues report in the journal AIDS that patients with chronic diarrhea and microsporidia infection had more severe malabsorption compared to those patients with diarrhea who had no microsporidia or identified pathogen. Wanke said that HIV-positive patients with chronic diarrhea may find relief by adding low-fat, simple carbohydrates to their diet.

"NAC: First Controlled Trial, Positive Results"

AIDS Treatment News (07/05/96) No. 250; P. 1; James, John S.

Results of the first controlled trial of NAC

(N-acetylcysteine), a low-cost potential treatment for certain non-HIV medical uses, were released in May. NAC is a popular "alternative" treatment that has been sold by AIDS buyers' clubs in the United States for years. The trial, which started in 1993 at Stanford University, was not able to determine if NAC improves patient survival. The trial did show, however, that NAC could increase levels of glutathione--an antioxidant needed for energy metabolism and cell functions, and that low levels of glutathione predict poor survival. Most people in the U.S. AIDS community believe NAC is not well-absorbed by the blood, but the Stanford trial found that glutathione levels did increase in the 27 patients who received NAC. The trial also found that low glutathione levels in CD4 T-cells were associated with increased risk of death. NAC was found to be safe, and the therapy was associated with increased survival.

"Court Rules That Tainted-Blood Commissioner Can Investigate Misconduct"

Lancet (07/06/96) Vol. 348, No. 9019; P. 52; Kondro, Wayne

Justice Horace Krever, the commissioner of Canada's tainted-blood inquiry, has been cleared by the country's Federal Court to make misconduct findings against 17 Red Cross and federal government officials. The court ruled that Krever did not act in "bad faith" or over-step his authority in issuing notices of potential misconduct against 64 individuals involved in the blood system's slow response to the contamination of donated blood. Krever says he will issue misconduct findings against 17 people, including George Weber, former secretary-general of the Canadian Red Cross Society (CRCS) and current director of the International Committee of the Red Cross. The CRCS says it may appeal the ruling, which would delay Krever's final report even longer.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:19-JUL-1996 11:04:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01I796L5RV28001C7H@PMDf.EOP.GOV> for

levi_j@a1.eop.gov; Fri, 19 Jul 1996 11:03:30 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <011796KYEw3O00007U@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 19 Jul 1996 11:03:21 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA19176; Fri,
19 Jul 1996 11:03:29 -0400
Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
===== END ATTACHMENT 2 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
003. email	From: Mail Link Monitor, To: Jeffrey Levi, Re: Confirmation: Appt. Request for Klein, Jennifer L [Personally Identifiable Information] [partial] (1 page)	07/19/1996	b(7)(C), b(7)(F), b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (WAVES RECEIPT)

CREATOR: Mail Link Monitor (MAILMGT) (SYS)

CREATION DATE/TIME:19-JUL-1996 14:54:42.78

SUBJECT: CONFIRMATION: APPT. REQUEST FOR KLEIN, JENNIFER L

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:NOT READ

TEXT:

FROM: WAVES OPERATIONS CENTER - ACO: (b)(6), (b)(7)c, (b)(7)f

Date: 07-19-1996

Time: 14:45:46

This message serves as confirmation of an appointment for the visitors listed below.

Appointment With: KLEIN, JENNIFER L

Appointment Date: 7/19/96

Appointment Time: 5:00:00 PM

Appointment Room: WW

Appointment Building: WH

Appointment Requested by: LEVI JEFFREY

Phone Number of Requestor: 21090

Comments:

WAVES APPOINTMENT NUMBER: U23341

If you have any questions regarding this appointment, please call the WAVES Center at 456-6742 and have the appointment number listed above available to the Access Control Officer answering your call.

[003]

TOTAL NUMBER OF NAMES SUBMITTED FOR ENTRY : 1

TOTAL NUMBER OF NAMES OF CLEARED FOR ENTRY: 1

SMOTHERMON, MC

(b)(6)

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:04:48.72

SUBJECT: RE: interns

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:24-JUL-1996 19:28:04.16

TEXT:

yes they should -- that's why I gave them the announcement

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:19-JUL-1996 12:01:00.00

SUBJECT: MMWR 07/19/96: Measles Pneumonitis Following Measles-Mumps-

TO: levi_j (levi_j@A1@CD) (WHO)

READ:19-JUL-1996 19:07:29.95

TEXT:

MORBIDITY AND MORTALITY WEEKLY REPORT

Centers for Disease Control and Prevention

July 19, 1996

Vol. 45, No. 28

Measles Pneumonitis Following Measles-Mumps-Rubella Vaccination of a Patient with HIV Infection, 1993

The Advisory Committee on Immunization Practices (ACIP) recommends measles-mumps-rubella vaccine (MMR) for all persons asymptotically infected with human immunodeficiency virus (HIV) and recommends that MMR be considered for all symptomatic HIV-infected persons who would otherwise be eligible for measles vaccine, because measles virus infection can cause severe illness and death in such persons (1,2). Serious or unusual adverse events in HIV-infected persons after receiving MMR have not been reported previously (1,2). This report summarizes the investigation of a case of progressive vaccine-associated measles pneumonitis in a person with acquired immunodeficiency syndrome and provides interim recommendations for the use of measles-containing vaccine among HIV-infected persons.

On September 3, 1992, a 20-year-old man with hemophilia A and HIV infection received MMR to fulfill a college prematriculation vaccination requirement for a second dose of measles-containing vaccine. He had received a previous dose of measles vaccine in 1973. His CD4+ T-lymphocyte count was reported as "too few to enumerate" in January, March, and August 1992. At the time of vaccination, he did not have HIV-related symptoms and was not taking antiretroviral therapy or prophylactic treatment for *Pneumocystis carinii* pneumonia (PCP).

On October 2, the patient was hospitalized because of increasing shortness of breath and dyspnea on exertion, and on October 5, PCP was diagnosed by methenamine silver stain following bronchoscopy with bronchoalveolar lavage. Therapy with intravenous pentamidine was initiated, and on October 8 the patient was discharged to complete treatment as an outpatient. His pulmonary symptoms resolved, and he was followed as an outpatient through November 1992, when he was lost to follow-up.

On July 30, 1993, he visited his physician and reported onset of night sweats, chills, and a nonproductive cough. Chest

radiograph demonstrated lingular and left lower lobe infiltrates. Outpatient treatment with atovaquone for presumptive PCP was initiated and continued until August 20 without improvement. On August 31, he was hospitalized because of worsening dyspnea, fever, nonproductive cough, and weight loss. Chest radiography revealed patchy infiltrates in the left lung and pleural effusion. Despite empiric treatment for PCP, fungal infection, Mycobacterium avium complex (MAC) disease, and other bacterial infections, he remained febrile without clinical improvement. Bronchoscopy with bronchoalveolar lavage and transbronchial biopsy on September 2 and September 23 did not provide a specific diagnosis, and cultures of pleural fluid were negative for bacterial, fungal, mycobacterial, and viral pathogens.

On October 6, an open-lung biopsy was performed. Biopsy specimens revealed numerous multinucleate giant cells, some of which contained both intranuclear and cytoplasmic eosinophilic inclusions suggestive of viral infection. A presumptive diagnosis of measles pneumonia was made, and therapy with intravenous gamma globulin was started. On October 22, measles virus was identified from tissue-culture cells inoculated with the lung biopsy tissue, and ribavirin therapy was initiated on October 23. The patient's condition stabilized, and he was discharged on October 29.

On November 12, he was hospitalized because of nausea and vomiting, increasing shortness of breath, and left upper quadrant abdominal pain. Chest radiograph demonstrated a right-sided nodular infiltrate and a left pneumothorax with effusion. The patient received treatment for presumptive MAC disease and esophageal candidiasis, and prophylaxis for PCP. A chest drainage catheter was placed and then removed before the patient was discharged on November 23.

On November 27, when he was hospitalized because of nausea, vomiting, and dehydration, chest radiograph demonstrated residual pneumothorax. Parenteral nutrition was initiated, and he was treated for presumptive MAC infection. Subsequent chest radiography demonstrated increased bilateral pulmonary infiltrates. Following the onset of encephalopathic changes on December 13, he died on December 17. No autopsy was performed.

The reported immediate cause of death was cytomegalovirus (CMV) encephalitis; pulmonary measles and MAC infection were listed as contributing causes. The diagnoses of CMV and MAC infection were based on clinical findings without laboratory confirmation.

The measles virus isolate recovered on October 22 from the patient's lung biopsy tissue was propagated in tissue-culture cells. Selected regions of the viral genome RNA were reverse transcribed, amplified by polymerase chain reaction, and subjected to sequence analysis, revealing a high degree of similarity to the Moraten measles vaccine virus strain. In 1995, the genomes of both the patient's virus isolate and the Moraten vaccine virus strain were completely sequenced and differed by only two nucleotides, each encoding an amino acid change. The essential identity of these two measles virus strains confirmed Moraten vaccine strain as the source of the virus isolated from the lung biopsy specimen. CDC was notified of these findings in March 1996, and supplemental sequence studies performed at CDC support the conclusion that Moraten

vaccine was the source for the measles virus isolate.

Reported by: JB Angel, MD, SA Udem, MD, DR Snyderman, MD, ME Keenan, MD, JT Noble, MD, RA DeLellis, MD, VA Sacco, MS, JL Hadler, MD, State Epidemiologist, Connecticut State Dept of Health. SM Lett, MD, A DeMaria, Jr, MD, State Epidemiologist, Massachusetts Dept of Public Health. Div of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention; Respiratory and Enteroviruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; Child Vaccine Preventable Diseases Br, Epidemiology and Surveillance Div, National Immunization Program, CDC.

Editorial Note: This report is the first known case of a serious adverse event following the documented administration of a measles-containing vaccine to a severely immunocompromised person with HIV infection. Serious adverse events after receipt of measles vaccine by persons with severe immunosuppression attributable to causes other than HIV infection have been reported previously (3), and measles vaccination is contraindicated in such persons. The case described in this report also is unusual because the patient did not have clinical onset of measles pneumonitis until almost 1 year after vaccination--a finding also not previously reported.

ACIP recommends the routine administration of MMR at age 12-15 months and a second dose at ages 4-6 years or 11-12 years (4). Adults without evidence of measles immunity should receive at least one dose of measles-containing vaccine (preferably MMR) unless otherwise contraindicated (5). Persons can be considered immune to measles if they 1) were born before 1957; 2) have documentation of physician-diagnosed measles; 3) have laboratory evidence of immunity to measles; or 4) have documentation of adequate vaccination (5).

Because of the increased risk for severe complications associated with measles infection and the absence of serious adverse events after measles vaccination among HIV-infected persons (1,2), ACIP has recommended that MMR be administered to all asymptomatic HIV-infected persons and that MMR be considered for administration to all symptomatic HIV-infected persons who would otherwise be eligible for measles vaccine--even though the immune response may be attenuated in such persons (1,2,5). There is a theoretical risk for an increase (probably transient) in HIV viral load following MMR vaccination because such effects have been observed with other vaccines (6). Specific studies of the effect, if any, of MMR vaccination on viral load are needed. Because of the case described in this report and other evidence indicating a diminished antibody response to measles vaccination among severely immunocompromised persons (7), ACIP is reevaluating the recommendations for vaccination of severely immunocompromised persons with HIV infection. In the interim, it may be prudent to withhold MMR or other measles containing vaccines from HIV-infected persons with evidence of severe immunosuppression, defined as 1) CD4+ T-lymphocyte counts less than 750 for children aged less than 12 months, less than 500 for children aged 1-5 years, or less than 200 for persons aged greater than or equal to 6 years; or 2) CD4+ T-lymphocytes constituting less than 15% of total lymphocytes for children aged less than 13 years (8,9).

ACIP continues to recommend MMR for HIV-infected persons

without evidence of measles immunity (5) who are not severely immunocompromised (8,9). Severely immunocompromised HIV-infected patients who are exposed to measles should receive immune globulin (IG), regardless of prior vaccination status (1). In addition, health-care providers should weigh the risks and benefits of measles vaccination or IG prophylaxis for severely immunocompromised HIV-infected patients who are at risk for measles exposure because of outbreaks or international travel.

Because the immunologic response to both live and killed antigen vaccines may decrease as HIV disease progresses (1,10), vaccination early in the course of HIV infection may be more likely to induce an immune response. Therefore, HIV-infected infants without severe immunosuppression should routinely receive MMR as soon as possible after their first birthday. Evaluation and testing of asymptomatic persons to identify HIV infection are not necessary before deciding to administer MMR or other measles-containing vaccine (1).

References

1. CDC. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993;42(no. RR-4):1-12.
2. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1994;43(no. RR-1).
3. Mitus A, Holloway A, Evans AE, Enders JF. Attenuated measles vaccine in children with acute leukemia. Am J Dis Child 1962;103:243-8.
4. CDC. Recommended childhood immunization schedule--United States, January-June 1996. MMWR 1996;44:940-3.
5. CDC. Measles prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1989;38(no. S-9).
6. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.
7. Palumbo P, Hoyt L, DeMasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992;11:1008-14.
8. CDC. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(no. RR-17).
9. CDC. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(no. RR-12):1-10.
10. Arpadi SM, Markowitz LE, Baughman AL, et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996;97:653-7.

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011798LG6B5S001H11@PMDf.EOP.GOV> for
levi_j@al.eop.gov; Fri, 19 Jul 1996 12:01:00 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <011798L9DYVC00007U@STORM.EOP.GOV> for
levi_j@al.eop.gov; Fri, 19 Jul 1996 12:00:51 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id MAA26083; Fri,
19 Jul 1996 12:01:00 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:07:47.38

SUBJECT: mmwr

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 16:10:17.81

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:25-JUL-1996 16:41:58.78

TO: Lahoma Romocki (ROMOCKI_L) (OPD)

READ:22-JUL-1996 09:46:58.22

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-JUL-1996 12:01:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: MMWR 07/19/96: Measles Pneumonitis Following Measles-Mumps-

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

MORBIDITY AND MORTALITY WEEKLY REPORT

Centers for Disease Control and Prevention

July 19, 1996

Vol. 45, No. 28

Measles Pneumonitis Following Measles-Mumps-Rubella Vaccination of
a Patient with HIV Infection, 1993

The Advisory Committee on Immunization Practices (ACIP)
recommends measles-mumps-rubella vaccine (MMR) for all persons
asymptotically infected with human immunodeficiency virus (HIV)
and recommends that MMR be considered for all symptomatic
HIV-infected persons who would otherwise be eligible for measles
vaccine, because measles virus infection can cause severe illness
and death in such persons (1,2). Serious or unusual adverse events
in HIV-infected persons after receiving MMR have not been reported
previously (1,2). This report summarizes the investigation of a
case of progressive vaccine-associated measles pneumonitis in a
person with acquired immunodeficiency syndrome and provides interim
recommendations for the use of measles-containing vaccine among
HIV-infected persons.

On September 3, 1992, a 20-year-old man with hemophilia A and HIV infection received MMR to fulfill a college prematriculation vaccination requirement for a second dose of measles-containing vaccine. He had received a previous dose of measles vaccine in 1973. His CD4+ T-lymphocyte count was reported as "too few to enumerate" in January, March, and August 1992. At the time of vaccination, he did not have HIV-related symptoms and was not taking antiretroviral therapy or prophylactic treatment for *Pneumocystis carinii* pneumonia (PCP).

On October 2, the patient was hospitalized because of increasing shortness of breath and dyspnea on exertion, and on October 5, PCP was diagnosed by methenamine silver stain following bronchoscopy with bronchoalveolar lavage. Therapy with intravenous pentamidine was initiated, and on October 8 the patient was discharged to complete treatment as an outpatient. His pulmonary symptoms resolved, and he was followed as an outpatient through November 1992, when he was lost to follow-up.

On July 30, 1993, he visited his physician and reported onset of night sweats, chills, and a nonproductive cough. Chest radiograph demonstrated lingular and left lower lobe infiltrates. Outpatient treatment with atovaquone for presumptive PCP was initiated and continued until August 20 without improvement. On August 31, he was hospitalized because of worsening dyspnea, fever, nonproductive cough, and weight loss. Chest radiography revealed patchy infiltrates in the left lung and pleural effusion. Despite empiric treatment for PCP, fungal infection, *Mycobacterium avium* complex (MAC) disease, and other bacterial infections, he remained febrile without clinical improvement. Bronchoscopy with bronchoalveolar lavage and transbronchial biopsy on September 2 and September 23 did not provide a specific diagnosis, and cultures of pleural fluid were negative for bacterial, fungal, mycobacterial, and viral pathogens.

On October 6, an open-lung biopsy was performed. Biopsy specimens revealed numerous multinucleate giant cells, some of which contained both intranuclear and cytoplasmic eosinophilic inclusions suggestive of viral infection. A presumptive diagnosis of measles pneumonia was made, and therapy with intravenous gamma globulin was started. On October 22, measles virus was identified from tissue-culture cells inoculated with the lung biopsy tissue, and ribavirin therapy was initiated on October 23. The patient's condition stabilized, and he was discharged on October 29.

On November 12, he was hospitalized because of nausea and vomiting, increasing shortness of breath, and left upper quadrant abdominal pain. Chest radiograph demonstrated a right-sided nodular infiltrate and a left pneumothorax with effusion. The patient received treatment for presumptive MAC disease and esophageal candidiasis, and prophylaxis for PCP. A chest drainage catheter was placed and then removed before the patient was discharged on November 23.

On November 27, when he was hospitalized because of nausea, vomiting, and dehydration, chest radiograph demonstrated residual pneumothorax. Parenteral nutrition was initiated, and he was treated for presumptive MAC infection. Subsequent chest radiography demonstrated increased bilateral pulmonary infiltrates. Following

the onset of encephalopathic changes on December 13, he died on December 17. No autopsy was performed.

The reported immediate cause of death was cytomegalovirus (CMV) encephalitis; pulmonary measles and MAC infection were listed as contributing causes. The diagnoses of CMV and MAC infection were based on clinical findings without laboratory confirmation.

The measles virus isolate recovered on October 22 from the patient's lung biopsy tissue was propagated in tissue-culture cells. Selected regions of the viral genome RNA were reverse transcribed, amplified by polymerase chain reaction, and subjected to sequence analysis, revealing a high degree of similarity to the Moraten measles vaccine virus strain. In 1995, the genomes of both the patient's virus isolate and the Moraten vaccine virus strain were completely sequenced and differed by only two nucleotides, each encoding an amino acid change. The essential identity of these two measles virus strains confirmed Moraten vaccine strain as the source of the virus isolated from the lung biopsy specimen. CDC was notified of these findings in March 1996, and supplemental sequence studies performed at CDC support the conclusion that Moraten vaccine was the source for the measles virus isolate.

Reported by: JB Angel, MD, SA Udem, MD, DR Snyderman, MD, ME Keenan, MD, JT Noble, MD, RA DeLellis, MD, VA Sacco, MS, JL Hadler, MD, State Epidemiologist, Connecticut State Dept of Health. SM Lett, MD, A DeMaria, Jr, MD, State Epidemiologist, Massachusetts Dept of Public Health. Div of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention; Respiratory and Enteroviruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; Child Vaccine Preventable Diseases Br, Epidemiology and Surveillance Div, National Immunization Program, CDC.

Editorial Note: This report is the first known case of a serious adverse event following the documented administration of a measles-containing vaccine to a severely immunocompromised person with HIV infection. Serious adverse events after receipt of measles vaccine by persons with severe immunosuppression attributable to causes other than HIV infection have been reported previously (3), and measles vaccination is contraindicated in such persons. The case described in this report also is unusual because the patient did not have clinical onset of measles pneumonitis until almost 1 year after vaccination--a finding also not previously reported.

ACIP recommends the routine administration of MMR at age 12-15 months and a second dose at ages 4-6 years or 11-12 years (4). Adults without evidence of measles immunity should receive at least one dose of measles-containing vaccine (preferably MMR) unless otherwise contraindicated (5). Persons can be considered immune to measles if they 1) were born before 1957; 2) have documentation of physician-diagnosed measles; 3) have laboratory evidence of immunity to measles; or 4) have documentation of adequate vaccination (5).

Because of the increased risk for severe complications associated with measles infection and the absence of serious adverse events after measles vaccination among HIV-infected persons (1,2), ACIP has recommended that MMR be administered to all asymptomatic HIV-infected persons and that MMR be considered for administration to all symptomatic HIV-infected persons who would

otherwise be eligible for measles vaccine--even though the immune response may be attenuated in such persons (1,2,5). There is a theoretical risk for an increase (probably transient) in HIV viral load following MMR vaccination because such effects have been observed with other vaccines (6). Specific studies of the effect, if any, of MMR vaccination on viral load are needed. Because of the case described in this report and other evidence indicating a diminished antibody response to measles vaccination among severely immunocompromised persons (7), ACIP is reevaluating the recommendations for vaccination of severely immunocompromised persons with HIV infection. In the interim, it may be prudent to withhold MMR or other measles containing vaccines from HIV-infected persons with evidence of severe immunosuppression, defined as 1) CD4+ T-lymphocyte counts less than 750 for children aged less than 12 months, less than 500 for children aged 1-5 years, or less than 200 for persons aged greater than or equal to 6 years; or 2) CD4+ T-lymphocytes constituting less than 15% of total lymphocytes for children aged less than 13 years (8,9).

ACIP continues to recommend MMR for HIV-infected persons without evidence of measles immunity (5) who are not severely immunocompromised (8,9). Severely immunocompromised HIV-infected patients who are exposed to measles should receive immune globulin (IG), regardless of prior vaccination status (1). In addition, health-care providers should weigh the risks and benefits of measles vaccination or IG prophylaxis for severely immunocompromised HIV-infected patients who are at risk for measles exposure because of outbreaks or international travel.

Because the immunologic response to both live and killed antigen vaccines may decrease as HIV disease progresses (1,10), vaccination early in the course of HIV infection may be more likely to induce an immune response. Therefore, HIV-infected infants without severe immunosuppression should routinely receive MMR as soon as possible after their first birthday. Evaluation and testing of asymptomatic persons to identify HIV infection are not necessary before deciding to administer MMR or other measles-containing vaccine (1).

References

1. CDC. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993;42(no. RR-4):1-12.
2. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1994;43(no. RR-1).
3. Mitus A, Holloway A, Evans AE, Enders JF. Attenuated measles vaccine in children with acute leukemia. Am J Dis Child 1962;103:243-8.
4. CDC. Recommended childhood immunization schedule--United States, January-June 1996. MMWR 1996;44:940-3.
5. CDC. Measles prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1989;38(no. S-9).
6. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.

7. Palumbo P, Hoyt L, DeMasio K, Oleske J, Connor E.
Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. *Pediatr Infect Dis J* 1992;11:1008-14.
8. CDC. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR* 1992;41(no. RR-17).
9. CDC. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR* 1994;43(no. RR-12):1-10.
10. Arpadi SM, Markowitz LE, Baughman AL, et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. *Pediatrics* 1996;97:653-7.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:19-JUL-1996 12:01:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01I798LG6B5S001H11@PMDf.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 19 Jul 1996 12:01:00 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <01I798L9DYVC00007U@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 19 Jul 1996 12:00:51 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id MAA26083; Fri,
19 Jul 1996 12:01:00 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:19-JUL-1996 17:48:40.03

SUBJECT: interns

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:19-JUL-1996 19:04:30.65

TEXT:

Jeff --

The interns wanted to know if they could attend the NORA meeting on Monday?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 READ RECEIPT)

CREATOR: POSTMASTER (SYS)

CREATION DATE/TIME:19-JUL-1996 19:24:00.00

SUBJECT: Auto reply from CRAFT_D

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:19-JUL-1996 19:35:41.72

TEXT:

I will be out until Wednesday, July 24. Micah Berman will be at my desk (65571), but will not be reading my emails. Micah will be assisting Jeremy while I am out. Please call if you've questions.

THANKS!

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: CN=Toby Donenfeld/O=OVP@OVP@LNGATE@EOPMRX

CREATION DATE/TIME:19-JUL-1996 17:48:00.00

SUBJECT: pre-meeting

TO: LEVI_J (LEVI_J@A1@CD) (WHO)

READ:19-JUL-1996 17:54:46.23

TEXT:

Message Creation Date was at 19-JUL-1996 17:49:00

the pre-meeting for the keystone meeting is scheduled for tuesday, july 30 from
1 - 2 p.m. hopefully in the ceremonial office.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 READ RECEIPT)

CREATOR: POSTMASTER (SYS)

CREATION DATE/TIME:19-JUL-1996 19:20:00.00

SUBJECT: Auto reply from RASCO_C

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:19-JUL-1996 19:20:45.13

TEXT:

I am out of the office for the remainder of the afternoon. I will
check email later tonight.

Please call Jill Pizzuto at 456-2249 if you need to reach me.

Thank you.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:29:15.01

SUBJECT: ADAP announcement

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:22-JUL-1996 09:01:21.78

CC: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 16:01:38.95

TEXT:

FYI -- Patsy is out of town on Tuesday with Shalala in Cleveland.
(No jokes about rivers being on fire.) If there is any way to do
the announcement of ADAP \$ on Monday, that would be great.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:19-JUL-1996 11:03:00.00

SUBJECT: CDC AIDS Daily Summary 07/19/96

TO: levi_j (levi_j@A1@CD) (WHO)

READ:19-JUL-1996 19:04:56.10

TEXT:

AIDS Daily Summary
July 19, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information.
Copyright 1996, Information, Inc., Bethesda, MD

"Merck's Sales Boosted Net 13% in Quarter"
"Firm Wilts on Positive News on AIDS Fight"
"Some With AIDS May Be Told to Shun Measles Vaccine"
"Asian Members Seek "Functional Cooperation" "
"American Lung Association Calls for Global Effort to Control TB"
"Scientist Calls for New Process to Accelerate Progress Toward
an AIDS Vaccine"
"Rifabutin Shows Efficacy in Treatment of AIDS-Related M. avium
Infection"
"Microsporidia Linked to Malabsorption and Wasting in AIDS
Patients"
"NAC: First Controlled Trial, Positive Results"
"Court Rules That Tainted-Blood Commissioner Can Investigate
Misconduct"

"Merck's Sales Boosted Net 13% in Quarter"
Wall Street Journal (07/19/96) P. B3; Naj, Amal Kumar
Strong sales of several Merck products, including its new AIDS drug Crixivan, helped boost the company's second-quarter profit 13 percent to \$972.1 million. Sales for the quarter increased 19 percent to \$4.91 billion, meeting Wall Street analysts' projections. Crixivan, Merck's new protease inhibitor, has already been prescribed for 30,000 patients since it became available two months ago and has generated \$27 million in sales. The company also reported strong sales for its Varivax chicken pox vaccine; Fosamax, an osteoporosis drug; and two

cholesterol-lowering drugs, Mevacor and Zocor.

"Firm Wilts on Positive News on AIDS Fight"

Houston Chronicle (07/18/96) P. 2C

Shares of the viatical settlement company Dignity Partners fell 77 percent after it announced late Tuesday that it would no longer buy life insurance policies from AIDS patients due to advances in treating the disease. The San Francisco business was the first public company to specialize in viatical settlements, and more than 95 percent of its customers were people with HIV or AIDS. The company said that progress in AIDS treatment presented at the XIth International Conference on AIDS last week could hurt its profits, which depend on being able to assess how long a person will live.

"Some With AIDS May Be Told to Shun Measles Vaccine"

Reuters (07/18/96)

Officials at the Centers for Disease Control and Prevention (CDC) said Thursday that they were considering telling some people with AIDS to avoid getting measles vaccinations. The concern arose after it was discovered that a 20-year-old man whose immune system was weakened by HIV died from pneumonitis caused by the measles virus. The man did not become ill until a year after he received the vaccine, and the cause of his illness was not discovered until last year, though he died in 1993. The CDC reported that this was the first known case of a serious complication from measles vaccination in an HIV-infected person with severely weakened immunity. The agency said that, for now, HIV-infected individuals who are not severely immunocompromised should continue to receive the combination measles-mumps-rubella vaccine.

"Asian Members Seek 'Functional Cooperation' "

Journal of Commerce (07/19/96) P. 4A

Countries in Southeast Asia plan to improve cooperation in such programs as scientific development and AIDS prevention and control, Indonesian Foreign Minister Ali Alatas said Thursday. Alatas said that the standing committee of the Association of Southeast Asian Nations would call for Asian foreign ministers to adopt a framework to give "functional cooperation" between member states a higher priority.

"American Lung Association Calls for Global Effort to Control TB"

Reuters (07/18/96)

Global cooperation is needed to prevent and control the spread of tuberculosis (TB), delegates to the American Lung Association Conference on Re-establishing Control of Tuberculosis in the United States reported. The group said that health departments should have greater legal authority to monitor and control TB, including the detention of unmanageable patients. Other recommendations included improved communication between TB and HIV treatment programs, and development of a new TB vaccine. Meeting notes were published in the July issue of the American Journal of Respiratory and Critical Care Medicine.

"Scientist Calls for New Process to Accelerate Progress Toward an AIDS Vaccine"

Reuters (07/18/96)

Richard T. Mahoney of the International Vaccine Institute in Seoul, South Korea, asserts that current AIDS vaccine development efforts are insufficient and that a comprehensive management system is necessary to yield results. In a commentary in the Spring issue of the AIDS and Public Policy Journal, he writes that current research should receive greater funding and that the "most appropriate system to accelerate development of an HIV vaccine is the consultative-group model." Currently, about \$25 million is being spent each year on vaccine development, but Mahoney says that some \$200 million to \$300 million a year will have to be invested to produce a single new vaccine.

"Rifabutin Shows Efficacy in Treatment of AIDS-Related M. avium Infection"

Reuters (07/18/96)

French researchers report that rifabutin is active against Mycobacterium avium alone and makes a significant contribution to combination therapy for the treatment of disseminated M. avium infection in AIDS patients. Dr. Bertrand Dautzenberg et al. at the Groupe Hospitalier Pitie-Salpetriere in Paris report their findings in the July issue of Antimicrobial Agents and Chemotherapy. Their study of 10 AIDS patients with M. avium infection found that rifabutin was effective after two weeks in seven of the individuals.

"Microsporidia Linked to Malabsorption and Wasting in AIDS Patients"

Reuters (07/18/96)

Microsporidia infection is related to malabsorption and malnutrition in AIDS patients with chronic diarrhea, say researchers at the New England Deaconess Hospital. Christine A. Wanke and colleagues report in the journal AIDS that patients with chronic diarrhea and microsporidia infection had more severe malabsorption compared to those patients with diarrhea who had no microsporidia or identified pathogen. Wanke said that HIV-positive patients with chronic diarrhea may find relief by adding low-fat, simple carbohydrates to their diet.

"NAC: First Controlled Trial, Positive Results"

AIDS Treatment News (07/05/96) No. 250; P. 1; James, John S.

Results of the first controlled trial of NAC (N-acetylcysteine), a low-cost potential treatment for certain non-HIV medical uses, were released in May. NAC is a popular "alternative" treatment that has been sold by AIDS buyers' clubs in the United States for years. The trial, which started in 1993 at Stanford University, was not able to determine if NAC improves patient survival. The trial did show, however, that NAC could increase levels of glutathione--an antioxidant needed for energy metabolism and cell functions, and that low levels of glutathione predict poor survival. Most people in the U.S. AIDS community

believe NAC is not well-absorbed by the blood, but the Stanford trial found that glutathione levels did increase in the 27 patients who received NAC. The trial also found that low glutathione levels in CD4 T-cells were associated with increased risk of death. NAC was found to be safe, and the therapy was associated with increased survival.

"Court Rules That Tainted-Blood Commissioner Can Investigate Misconduct"

Lancet (07/06/96) Vol. 348, No. 9019; P. 52; Kondro, Wayne

Justice Horace Krever, the commissioner of Canada's tainted-blood inquiry, has been cleared by the country's Federal Court to make misconduct findings against 17 Red Cross and federal government officials. The court ruled that Krever did not act in "bad faith" or over-step his authority in issuing notices of potential misconduct against 64 individuals involved in the blood system's slow response to the contamination of donated blood. Krever says he will issue misconduct findings against 17 people, including George Weber, former secretary-general of the Canadian Red Cross Society (CRCS) and current director of the International Committee of the Red Cross. The CRCS says it may appeal the ruling, which would delay Krever's final report even longer.

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:19-JUL-1996 11:04:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011796L5RV28001C7H@PMDf.EOP.GOV> for levi_j@al.eop.gov; Fri, 19 Jul 1996 11:03:30 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <011796KYEw3O00007U@STORM.EOP.GOV> for levi_j@al.eop.gov; Fri, 19 Jul 1996 11:03:21 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA19176; Fri, 19 Jul 1996 11:03:29 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:14:14.30

SUBJECT: Keystone

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 16:00:22.36

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:21-JUL-1996 19:15:34.03

TEXT:

Here's where things stand for the Keystone - OVP meeting

(1) There will be a pre-meeting with agency folks on July 30th with Phil Lee, Vladeck, Paul, Fauci, Kessler, Kizer, Sumaya/O'Neill.

Purpose:

- review Keystone findings
- get reaction and sign off (they should have been briefed by staff before hand)
- get commitment to help fund the pilot project (\$300,000 over 18 months -- covers three fiscal years, this should be easy)
- get commitment to provide in kind staff.

(2) Pre-brief of VP on August 2nd:

Attendees:

- PF, Greg, Toby, Jeff, Jane
- Bill Paul

Purpose:

- (a) update on science/Vancouver from Bill Paul
- (b) presentation of Federal Research plan
- (c) Implementation of Levine Report (apparently VP has been reading about it and asking questions)
- (d) follow up on vaccines and microbicides from Feb. meeting
- (e) review of Keystone

all this in 30 minutes

(3) Meeting -- probably morning of August 2nd -- one hour

(4) Alexandra Levine will represent Advisory Council

Same government folks as above will be there as well

person representing home (still to be found) for the pilot project

(5) written materials to do:

- memo and q&a on Keystone for VP (Toby)
- press statement

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 10:45:29.85

SUBJECT: lest I forget

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 15:57:37.56

TEXT:

Lisa Jacobs at Justice called recently looking for things for Reno to do on AIDS -- the AG has expressed an interest in doing more.

I suggested two things to Lisa today -- as a starting point --

(1) a meeting with discrimination folks -- this would generally be a very positive session about how well DOJ is doing on ADA enforcement -- a good chance to give better publicity to this.

(2) a meeting with prisons folks -- to address some BOP issues, but also to explore how DOJ can help set a standard of care (i.e., what Patricia's been working on).

I gave Lisa some community/council folks to talk with as part of her research.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:34:06.68

SUBJECT: finding me

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:21-JUL-1996 16:55:37.65

TO: Jeremy D. Benami (BENAMI_J) (WHO)
READ:22-JUL-1996 09:02:34.80

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:22-JUL-1996 08:27:51.22

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:22-JUL-1996 19:59:52.40

TO: Dorothy K. Craft (CRAFT_D) (OPD)
READ:25-JUL-1996 17:07:28.88

TO: Richard J. Turman (TURMAN_R) (OMB)
READ:19-JUL-1996 20:08:58.61

TO: William G. White (WHITE_W) (OMB)
READ:22-JUL-1996 08:47:19.25

TO: Nancy-Ann E. Min (MIN_N) (OMB)
READ:20-JUL-1996 14:25:19.81

TEXT:

I am -- at this moment -- trying to get out of here for a week's vacation. Pagers do not work on this mountaintop -- so if you need me -- you can reach me by calling
540-743-1728

Thanks. I'll be back on the 29th.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 18:31:27.29

SUBJECT: Keystone prep meeting

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 15:59:39.60

TEXT:

this is the meeting with administration end of folks re Keystone meeting with VP. It should be Phil, Bill Paul, Vladeck, Ken Kizer, Ciro or Joe.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-JUL-1996 17:49:00.00

ATT BODYPART TYPE:E

ATT CREATOR: CN=Toby Donenfeld/O=OVP

ATT SUBJECT: pre-meeting

ATT TO: LEVI_J (LEVI_J@A1@CD)

TEXT:

Message Creation Date was at 19-JUL-1996 17:49:00

the pre-meeting for the keystone meeting is scheduled for tuesday, july 30 from 1 - 2 p.m. hopefully in the ceremonial office.

===== END ATTACHMENT 1 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
004. email	From: Jeffrey Levi, To: Jeffrey Levi, Re: Appt. Request - Smothermon, MC [Personally Identifiable Information] [partial] (1 page)	07/19/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (WAVES REQUEST)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 14:34:54.34

SUBJECT: Appt. request - Smothermon, MC

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:NOT READ

TEXT:

Date	Appointment with
19-Jul-1996	KLEIN, JENNIFER L

Room No. Bldg.	Requested by	Phone #
2FL/WW WH	Jeffrey Levi	632-1090

Comments:

TIME	VISITOR'S LAST, FIRST NAME	BIRTHDATE	SOC. SEC. #
------	----------------------------	-----------	-------------

05:00pm	Smothermon	MC	(b)(6)	- -
---------	------------	----	--------	-----

[004]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:20:31.40

SUBJECT: Two things

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:21-JUL-1996 16:52:49.96

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 16:00:48.43

CC: Jeremy D. Benami (BENAMI_J) (WHO)
READ:22-JUL-1996 08:59:50.36

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:19-JUL-1996 19:37:01.00

TEXT:

(1) Jeremy mentioned your interest in activities around the quilt in October. There will be millions of things going on -- when it gets closer we will compile a list and make some recommendations. If you would like to read names at the quilt display -- this can be arranged -- for you and other DPC staff (or other WH officials as well) -- let us know and we will speak to the Names Project people. If there are specific names you would like to read, I believe that can be arranged also.

(2) The Vice President is meeting on August 2nd with the Keystone Dialogue group working on AIDS clinical effectiveness research -- this is the public-private collaboration the VP asked for at the February meeting with the drug companies. The result is a recommendation for an on-going pilot project among government, researchers, industry, patients, and third party payors to become something of a "bully pulpit" for identifying key research questions that are not being answered. The federal government will be asked to kick in some money (about \$350,000) for the 18-month pilot project. It is actually a very positive outcome--it is the most positive interaction between industry and the rest of the AIDS community that I have seen in all my years in this business.

Is this something you want to attend or in some other way be involved with?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Richard Socarides (SOCARIDES_R) (WHO)

CREATION DATE/TIME:19-JUL-1996 09:24:24.36

SUBJECT: RE: Tom Duane

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:19-JUL-1996 09:33:55.91

CC: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 15:57:14.21

TEXT:

thanks!!!

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 14:48:37.24

SUBJECT: spoke with Kevin

TO: Jeremy D. Benami (BENAMI_J) (WHO)

READ:19-JUL-1996 16:53:01.33

TEXT:

...and he is having Shalala and Lee read this over the weekend;
they will have a unified response on Monday; we will meet Tuesday
or Wednesday until it is done...

...I, of course, will be on vacation...except to come back to
explain the AIDS drug announcement -- I will call you before i
escape from here.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
005. email	From: Mail Link Monitor, To: Jeffrey Levi, Re: Confirmation: Appt. Request for Donenfeld, Toby A [Personally Identifiable Information] [partial] (1 page)	07/19/1996	b(7)(C), b(7)(F), b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (WAVES RECEIPT)

CREATOR: Mail Link Monitor (MAILMGT) (SYS)

CREATION DATE/TIME:19-JUL-1996 14:41:22.17

SUBJECT: CONFIRMATION: APPT. REQUEST FOR DONENFELD, TOBY A

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:19-JUL-1996 16:15:33.58

TEXT:

FROM: WAVES OPERATIONS CENTER - ACO: (b)(6), (b)(7)c, (b)(7)f

Date: 07-19-1996

Time: 14:38:04

This message serves as confirmation of an appointment for the visitors listed below.

Appointment With: DONENFELD, TOBY A

Appointment Date: 7/19/96

Appointment Time: 4:30:00 PM

Appointment Room: 284

Appointment Building: OEOB

Appointment Requested by: LEVI JEFFREY

Phone Number of Requestor: 21090

Comments:

WAVES APPOINTMENT NUMBER: U23334

If you have any questions regarding this appointment, please call the WAVES Center at 456-6742 and have the appointment number listed above available to the Access Control Officer answering your call.

TOTAL NUMBER OF NAMES SUBMITTED FOR ENTRY : 1

TOTAL NUMBER OF NAMES OF CLEARED FOR ENTRY: 1

SMOTHERMON, MC

(b)(6)

[005]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:24:58.07

SUBJECT: Meeting re long-term planning

TO: Dorothy K. Craft (CRAFT_D) (OPD)

READ:25-JUL-1996 14:14:00.91

CC: Jeremy D. Benami (BENAMI_J) (WHO)

READ:22-JUL-1996 09:00:57.20

TEXT:

Dorothy--welcome back and congratulations. You thought you could hide from lots of e-mails on your return by changing your name BEFORE you were married. Wait till Al D'Amato hears about this! I have a favor if you have time...I mentioned to Jeremy that we had been approached by AIDS Action Council about having a discussion with some AIDS groups about some long-term planning on HIV policy. Jeremy expressed interest in attending. Could you let me know some dates that are good with Jeremy -- and then I'll get some from Patsy and see what works for AIDS Action -- in the first few weeks in August?
Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:26:36.82

SUBJECT: the attached

TO: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 16:01:10.77

TEXT:

Christine asked to meet with us and a group of AIDS folks re long-term issues (e.g., post November). I checked with Jeremy about whether it was appropriate -- he said yes, and expressed interest in attending -- hence the attached. I assume you are interested...let me know.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-JUL-1996 19:21:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jeffrey Levi

ATT SUBJECT: Meeting re long-term planning

ATT TO: Dorothy K. Craft (CRAFT_D)

ATT CC: Jeremy D. Benami (BENAMI_J)

TEXT:

Dorothy--welcome back and congratulations. You thought you could hide from lots of e-mails on your return by changing your name BEFORE you were married. Wait till Al D'Amato hears about this! I have a favor if you have time...I mentioned to Jeremy that we had been approached by AIDS Action Council about having a discussion with some AIDS groups about some long-term planning on HIV policy. Jeremy expressed interest in attending. Could you let me know some dates that are good with Jeremy -- and then I'll get some from Patsy and see what works for AIDS Action -- in the first few weeks in August?

Thanks.

===== END ATTACHMENT 1 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
006. email	From: Jeffrey Levi, To: Jeffrey Levi, Re: Appt. Request - Smothermon, MC [Personally Identifiable Information] [partial] (1 .page)	07/19/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (WAVES REQUEST)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 14:34:07.67

SUBJECT: Appt. request - Smothermon, MC

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:NOT READ

TEXT:

Date	Appointment with
19-Jul-1996	DONENFELD, TOBY A

Room No.	Bldg.	Requested by	Phone #
284	EOB	Jeffrey Levi	632-1090

Comments:

TIME	VISITOR'S LAST, FIRST NAME	BIRTHDATE	SOC. SEC. #
------	----------------------------	-----------	-------------

04:30pm	Smothermon	MC	(b)(6)	- -
---------	------------	----	--------	-----

[006]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 11:55:15.60

SUBJECT: Memo to POTUS re AIDS drugs

TO: Carol H. Rasco (RASCO_C) (WHO)
READ:19-JUL-1996 12:49:42.21

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 15:59:03.33

CC: Jeremy D. Benami (BENAMI_J) (WHO)
READ:19-JUL-1996 16:38:38.53

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:19-JUL-1996 19:32:07.00

TEXT:

You are about to receive from OMB a draft memo re the AIDS drugs. It looks fine to me -- though it seems amazing that we are having such a hard time with HHS over the .77% cut in the administrative costs as an offset.

One small concern: our capacity to estimate exactly how many people will be served by this amendment is extremely limited. HRSA is a data-free zone in terms of learning who is being served by this program; the number of people who will take this therapy and STAY on it for 12 months is unknown; the cost of these drugs keeps shifting (downward, fortunately) -- this is our best estimate of what can be done to meet the demand. We should be VERY careful not to say publicly a specific number of people who will get protease inhibitors -- because with any slight change in any of the assumptions, the number could shift dramatically. But this is a number HHS and OMB and this office felt was a good target.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:07:28.23

SUBJECT: see first item

TO: Nancy-Ann E. Min (MIN_N) (OMB)
READ:19-JUL-1996 19:25:21.85

TO: Richard J. Turman (TURMAN_R) (OMB)
READ:21-JUL-1996 13:31:52.79

TO: William G. White (WHITE_W) (OMB)
READ:19-JUL-1996 19:16:43.78

TEXT:

seems like there could be a matching grant program here for ADAP?

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-JUL-1996 11:03:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 07/19/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
July 19, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

"Merck's Sales Boosted Net 13% in Quarter"

"Firm Wilts on Positive News on AIDS Fight"

"Some With AIDS May Be Told to Shun Measles Vaccine"

"Asian Members Seek "Functional Cooperation" "

"American Lung Association Calls for Global Effort to Control TB"

"Scientist Calls for New Process to Accelerate Progress Toward an AIDS Vaccine"

"Rifabutin Shows Efficacy in Treatment of AIDS-Related M. avium

Infection"

"Microsporidia Linked to Malabsorption and Wasting in AIDS Patients"

"NAC: First Controlled Trial, Positive Results"

"Court Rules That Tainted-Blood Commissioner Can Investigate Misconduct"

"Merck's Sales Boosted Net 13% in Quarter"

Wall Street Journal (07/19/96) P. B3; Naj, Amal Kumar

Strong sales of several Merck products, including its new AIDS drug Crixivan, helped boost the company's second-quarter profit 13 percent to \$972.1 million. Sales for the quarter increased 19 percent to \$4.91 billion, meeting Wall Street analysts' projections. Crixivan, Merck's new protease inhibitor, has already been prescribed for 30,000 patients since it became available two months ago and has generated \$27 million in sales. The company also reported strong sales for its Varivax chicken pox vaccine; Fosamax, an osteoporosis drug; and two cholesterol-lowering drugs, Mevacor and Zocor.

"Firm Wilts on Positive News on AIDS Fight"

Houston Chronicle (07/18/96) P. 2C

Shares of the viatical settlement company Dignity Partners fell 77 percent after it announced late Tuesday that it would no longer buy life insurance policies from AIDS patients due to advances in treating the disease. The San Francisco business was the first public company to specialize in viatical settlements, and more than 95 percent of its customers were people with HIV or AIDS. The company said that progress in AIDS treatment presented at the XIth International Conference on AIDS last week could hurt its profits, which depend on being able to assess how long a person will live.

"Some With AIDS May Be Told to Shun Measles Vaccine"

Reuters (07/18/96)

Officials at the Centers for Disease Control and Prevention (CDC) said Thursday that they were considering telling some people with AIDS to avoid getting measles vaccinations. The concern arose after it was discovered that a 20-year-old man whose immune system was weakened by HIV died from pneumonitis caused by the measles virus. The man did not become ill until a year after he received the vaccine, and the cause of his illness was not discovered until last year, though he died in 1993. The CDC reported that this was the first known case of a serious complication from measles vaccination in an HIV-infected person with severely weakened immunity. The agency said that, for now, HIV-infected individuals who are not severely immunocompromised should continue to receive the combination measles-mumps-rubella vaccine.

"Asian Members Seek 'Functional Cooperation'."

Journal of Commerce (07/19/96) P. 4A

Countries in Southeast Asia plan to improve cooperation in

such programs as scientific development and AIDS prevention and control, Indonesian Foreign Minister Ali Alatas said Thursday. Alatas said that the standing committee of the Association of Southeast Asian Nations would call for Asian foreign ministers to adopt a framework to give "functional cooperation" between member states a higher priority.

"American Lung Association Calls for Global Effort to Control TB"
Reuters (07/18/96)

Global cooperation is needed to prevent and control the spread of tuberculosis (TB), delegates to the American Lung Association Conference on Re-establishing Control of Tuberculosis in the United States reported. The group said that health departments should have greater legal authority to monitor and control TB, including the detention of unmanageable patients. Other recommendations included improved communication between TB and HIV treatment programs, and development of a new TB vaccine. Meeting notes were published in the July issue of the American Journal of Respiratory and Critical Care Medicine.

"Scientist Calls for New Process to Accelerate Progress Toward an AIDS Vaccine"
Reuters (07/18/96)

Richard T. Mahoney of the International Vaccine Institute in Seoul, South Korea, asserts that current AIDS vaccine development efforts are insufficient and that a comprehensive management system is necessary to yield results. In a commentary in the Spring issue of the AIDS and Public Policy Journal, he writes that current research should receive greater funding and that the "most appropriate system to accelerate development of an HIV vaccine is the consultative-group model." Currently, about \$25 million is being spent each year on vaccine development, but Mahoney says that some \$200 million to \$300 million a year will have to be invested to produce a single new vaccine.

"Rifabutin Shows Efficacy in Treatment of AIDS-Related M. avium Infection"
Reuters (07/18/96)

French researchers report that rifabutin is active against Mycobacterium avium alone and makes a significant contribution to combination therapy for the treatment of disseminated M. avium infection in AIDS patients. Dr. Bertrand Dautzenberg et al. at the Groupe Hospitalier Pitie-Salpetriere in Paris report their findings in the July issue of Antimicrobial Agents and Chemotherapy. Their study of 10 AIDS patients with M. avium infection found that rifabutin was effective after two weeks in seven of the individuals.

"Microsporidia Linked to Malabsorption and Wasting in AIDS Patients"
Reuters (07/18/96)

Microsporidia infection is related to malabsorption and malnutrition in AIDS patients with chronic diarrhea, say researchers at the New England Deaconess Hospital. Christine A.

Wanke and colleagues report in the journal AIDS that patients with chronic diarrhea and microsporidia infection had more severe malabsorption compared to those patients with diarrhea who had no microsporidia or identified pathogen. Wanke said that HIV-positive patients with chronic diarrhea may find relief by adding low-fat, simple carbohydrates to their diet.

"NAC: First Controlled Trial, Positive Results"

AIDS Treatment News (07/05/96) No. 250; P. 1; James, John S.

Results of the first controlled trial of NAC (N-acetylcysteine), a low-cost potential treatment for certain non-HIV medical uses, were released in May. NAC is a popular "alternative" treatment that has been sold by AIDS buyers' clubs in the United States for years. The trial, which started in 1993 at Stanford University, was not able to determine if NAC improves patient survival. The trial did show, however, that NAC could increase levels of glutathione--an antioxidant needed for energy metabolism and cell functions, and that low levels of glutathione predict poor survival. Most people in the U.S. AIDS community believe NAC is not well-absorbed by the blood, but the Stanford trial found that glutathione levels did increase in the 27 patients who received NAC. The trial also found that low glutathione levels in CD4 T-cells were associated with increased risk of death. NAC was found to be safe, and the therapy was associated with increased survival.

"Court Rules That Tainted-Blood Commissioner Can Investigate Misconduct"

Lancet (07/06/96) Vol. 348, No. 9019; P. 52; Kondro, Wayne

Justice Horace Krever, the commissioner of Canada's tainted-blood inquiry, has been cleared by the country's Federal Court to make misconduct findings against 17 Red Cross and federal government officials. The court ruled that Krever did not act in "bad faith" or over-step his authority in issuing notices of potential misconduct against 64 individuals involved in the blood system's slow response to the contamination of donated blood. Krever says he will issue misconduct findings against 17 people, including George Weber, former secretary-general of the Canadian Red Cross Society (CRCS) and current director of the International Committee of the Red Cross. The CRCS says it may appeal the ruling, which would delay Krever's final report even longer.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:19-JUL-1996 11:04:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <011796L5RV28001C7H@PMDf.EOP.GOV> for

levi_j@a1.eop.gov; Fri, 19 Jul 1996 11:03:30 -0400 (EDT)
Received: from aspen3.aspensys.com (aspensys3.aspensys.com)
by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <01I796KYEw3O00007U@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Fri, 19 Jul 1996 11:03:21 -0700 (MST)
Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA19176; Fri,
19 Jul 1996 11:03:29 -0400
Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com
Precedence: bulk
Originator: aidsnews@cdcnac.aspensys.com
X-Comment: CDC National AIDS Clearinghouse
X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas
===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:19-JUL-1996 19:37:01.61

SUBJECT: And the secret number is...

TO: Jennifer L. Klein (KLEIN_J) (OPD)

READ:19-JUL-1996 19:43:32.79

TEXT:

540-743-1728 if you need me next week. Have fun.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Carol H. Rasco (RASCO_C) (WHO)

CREATION DATE/TIME:19-JUL-1996 12:59:26.46

SUBJECT: RE: Memo to POTUS re AIDS drugs

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:19-JUL-1996 13:22:25.09

CC: Patsy Fleming (FLEMING_P) (WHO)

READ:24-JUL-1996 15:59:25.79

CC: Jeremy D. Benami (BENAMI_J) (WHO)

READ:19-JUL-1996 17:45:37.35

CC: Elizabeth E. Drye (DRYE_E) (OPD)

READ:19-JUL-1996 13:53:27.05

TEXT:

I have read it and am letting Nancy-Ann know I am fine. I did mention the issue briefly to Kevin this a.m. in a conversation on another topic.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
007. email	From: Donald Abrams, To: Jeffrey Levi, Re: Has there been a Novick Siting? (1 page)	07/20/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:21-JUL-1996 15:18:43.35

SUBJECT: Alexandra Levine

TO: Toby A. Donenfeld (DONENF_T) Autoforward to: Remote Addressee (Toby
Donenfeld@LNGATE@EOPMRX) (VPO)
READ:NOT READ

TEXT:

Alexandra Levine

chair

Research Subcommittee

Presidential Advisory Council on HIV/AIDS

phone: 213-764-3913

fax: 213-764-0060

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
008. email	From: Carol Rasco, To: Jeffrey Levi, Re: Two Things [personal] [partial] (1 page)	07/21/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Carol H. Rasco (RASCO_C) (WHO)

CREATION DATE/TIME:21-JUL-1996 16:54:53.21

SUBJECT: RE: Two things

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:22-JUL-1996 18:27:46.43

CC: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 11:51:21.83

CC: Jeremy D. Benami (BENAMI_J) (WHO)
READ:22-JUL-1996 10:52:03.41

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:22-JUL-1996 10:33:25.20

TEXT:

a. QUILT: I would like to talk with the staff (or you and Jeremy can)...I think it would be absolutely terrific if the staff who wished would read names...wow, what an opportunity. I will look forward to other things you recommend.

b. August 2: (b)(6)

(b)(6) (b)(6)
...we will keep you posted as I know more.
Thanks so much.

[008]

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
009. email	From: Jeffrey Levi, To: Donald Abrams, Re: Has there been a Novick Siting? (1 page)	07/21/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: dabrams@sfajds.ucsf.edu@INET@EOPMRX

CREATION DATE/TIME:21-JUL-1996 15:15:00.00

SUBJECT: AutoResponse

TO: Jeffrey Levi (LEVI_J@A1@CD) (WHO)

READ:21-JUL-1996 15:16:52.93

TEXT:

I will be away from my desk until July 21 and may not have access to e-mail the entire time away. I can be reached in Vancouver, BC at 604-688-1234 until July 12.

Donald Abrams, M.D.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:21-JUL-1996 15:16:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I7C7YL8AM8001WDN@PMDF.EOP.GOV> for LEVI_J@a1.eop.gov; Sun, 21 Jul 1996 15:15:44 -0400 (EDT)

Received: from sfajds.ucsf.edu by STORM.EOP.GOV (PMDF V5.0-7 #6879)

id <01I7C7YCO6SS00007U@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Sun, 21 Jul 1996 15:15:33 -0700 (MST)

Received: from by sfajds.ucsf.edu (NTMail 3.01.03) id ka052218; Sun, 21 Jul 1996 12:21:25 -0700

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: bgw2@NIP1.EM.CDC.GOV@INET@EOPMRX

CREATION DATE/TIME:21-JUL-1996 13:28:00.00

SUBJECT: FW: Status and Trends of the HIV/AIDS Pandemic (J-Z)

TO: Linnan, Michael J. (MJL1@WONDER.EM.CDC.GOV@INET@EOPMRX)
READ:NOT READ

TO: Jaffe, Harold (hwjl@CIDDAS1.EM.CDC.GOV@INET@EOPMRX)
READ:NOT READ

TO: Nieburg, Phil (pinl@cpsodl.em.cdc.gov@INET@EOPMRX)
READ:NOT READ

TO: Moses, Steve (smm7@cpsstdl.em.cdc.gov@INET@EOPMRX)
READ:NOT READ

TO: Jones, T. Steve (tsjl@ODDHIV1.EM.CDC.GOV@INET@EOPMRX)
READ:NOT READ

TO: Limpakarnjanarat, Khanchit (kxl8@BANGKOK.EM.CDC.GOV@INET@EOPMRX)
READ:NOT READ

TO: Shepherd, H.R. (Sabin Fndtn) (102416.2336@compuserve.com@INET@EOPMRX)
READ:NOT READ

TO: Lu, Yichen (Virus Res Inst) (72054.701@compuserve.com@INET@EOPMRX)
READ:NOT READ

TO: Nelson, Kenrad (JHU) (cchandle@share.sph.jhu.edu@INET@EOPMRX)
READ:NOT READ

TO: 'Khamboonruang, Chirasak (CMU)' (chirasak@cmu.chiangmai.ac.th@INET@EOPMRX)
READ:NOT READ

TO: van der Groen, Guido (ITM Be) (cmaeckelbergh@itg.be@INET@EOPMRX)
READ:NOT READ

TO: Miramontes, Helen (UCSF.itsa) (helenmm@itsa.ucsf.edu@INET@EOPMRX)
READ:NOT READ

TO: 'Sato, Hironori (NIH Tokyo)' (hirosato@nih.go.jp@INET@EOPMRX)
READ:NOT READ

TO: 'Levine, Alexandra (c/o Hornor)' (hornor@hsc.usc.edu@INET@EOPMRX)
READ:NOT READ

TO: Maynard, Jim (PATH Seattle) (jmaynard@path.org@INET@EOPMRX)
READ:NOT READ

TO: McNeil, John (WRAIR/HJF) (jmcneil@hiv.hjf.org@INET@EOPMRX)
READ:NOT READ

TO: Otani, Junko (IBRD) (jotani@worldbank.org@INET@EOPMRX)
READ:NOT READ

TO: Kansaku, Shinjiro (JICWELS) (kansaku@jicwels.or.jp@INET@EOPMRX)
READ:NOT READ

TO: 'Levi, Jeff (ONAP, White House)' (LEVI_J@A1@CD) (WHO)
READ:21-JUL-1996 15:16:16.50

TO: Longini, Ira (Emory) (longini@fox.sph.emory.edu@INET@EOPMRX)
READ:NOT READ

TO: Mathieson, Bonnie (MathiesB@od31em1.od.nih.gov@INET@EOPMRX)
READ:NOT READ

TO: Smith, Mark (Kaiser Found.) (msmith@kff.org@INET@EOPMRX)
READ:NOT READ

TO: Narumol Silarug (nxs3 MOPH Th) (nxs3@health.moph.go.th@INET@EOPMRX)
READ:NOT READ

TO: Russell, Philip (@aol.com) (PKRussell@aol.com@INET@EOPMRX)
READ:NOT READ

TO: Vermund, Sten (U Ala) (sten@geomed.dom.uab.edu@INET@EOPMRX)
READ:NOT READ

TO: Taylor, Dave & Pam (Peru) (taylor@namrid.sld.pe@INET@EOPMRX)
READ:NOT READ

TO: Kitayaporn, Dwip (Mahidol) (tmdkt@mahidol.ac.th@INET@EOPMRX)
READ:NOT READ

TO: Lee, Tun-Hou (Harvard SPH) (tunhoule@hsph.harvard.edu@INET@EOPMRX)
READ:NOT READ

TO: Koff, Wayne (UBI) (waynek@cerf.net@INET@EOPMRX)
READ:NOT READ

TO: Wiwat Peerapatanapokin (UCLA) (wiwat@pop.ben2.ucla.edu@INET@EOPMRX)
READ:NOT READ

TO: Yamazaki, Shudo (NIH Japan) (YAMAZAKI@nih.go.jp@INET@EOPMRX)
READ:NOT READ

TO: 'Sidharta, Yuwono (personal)' (yuwono@pusdata.dprin.go.id@INET@EOPMRX)
READ:NOT READ

TEXT:

Forwarded, FYI.

Date: Thu, 18 Jul 1996 09:30:14 -0400 (EDT)
From: Daniel Tarantola <danielt@hsph.harvard.edu>
To: "Weniger, Bruce" <bgw2@NIP1.EM.CDC.GOV>
Subject: Status and Trends of the HIV/AIDS Pandemic (fwd)

--
Dear Bruce,

It was a pleasure working with you in Vancouver. I would be grateful if you could forward the message that follows to your mailing list.

Greetings,

A Satellite Symposium on "The Status and Trends of the Global HIV/AIDS Pandemic" was held in Vancouver on 5-6 July, immediately before the XI International Conference on AIDS. A 38 page report on this subject was issued and widely distributed at the conference, both in English and French.

The Symposium was jointly organized by the FXB Center of the Harvard School of Public Health, AIDSCAP and UNAIDS.

The English version of this document can be downloaded from either of the following web sites:

<http://www.fxb.org> or: <http://www.aimnet.com/~jchin>

The French version can be mailed on request. A Spanish version will be forthcoming.

Daniel Tarantola
<danielt@hsph.harvard.edu>
FXB Center
Harvard School of Public Health

===== ATTACHMENT 1 =====
ATT CREATION TIME/DATE:21-JUL-1996 13:29:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0117C48LWAZ40024QO@PMDf.EOP.GOV> for
LEVI_J@a1.eop.gov; Sun, 21 Jul 1996 13:28:30 -0400 (EDT)

Received: from cdc1 (cdc1.cdc.gov) by STORM.EOP.GOV (PMDF V5.0-7 #6879)
id <0117C48DCGT200007U@STORM.EOP.GOV> for LEVI_J@a1.eop.gov; Sun,
21 Jul 1996 13:28:18 -0700 (MST)

Received: from SmtOut.em.cdc.gov by cdc1 (5.0/SMI-SVR4) id AA00273; Sun,
21 Jul 1996 13:28:02 -0400

Received: by SmtOut.em.cdc.gov with Microsoft Mail id
<31F1F7E2@SmtOut.em.cdc.gov>; Sun, 21 Jul 1996 13:26:58 -0500 (EST)

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:22-JUL-1996 16:52:13.33

SUBJECT: Trying again

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:22-JUL-1996 18:28:56.27

TEXT:

Let me try this again ... clearly I cannot type, think, and answer the phones at the same time.

A couple of things:

1. Cindy Hall called wanting info about the Henry M. Jackson firings. She's getting phone calls and had heard you and PF had a meeting scheduled. She'd really like any info that you have.

2. Shelly Gordon wants to talk to you about ADAP when you get a chance.

3. The Strategy --

There are some things I need your help/judgement on:

- NIH. They have not seen the 7 goals, do you think we need to run them by Wendy/Jack?

Do you remember what concerns Wendy had about the civil rights sections?

The new text provided by NIH was disjointed, poorly written, and quite parochial, parts in my opinion were not appropriate for a National (rather than an NIH) plan. Parts of the new text provided contradicted Wendy's written comments (for example, on the priority of adolescent research.) They also proposed language which essentially denied the differing opinions (basic/empirical) among vaccine developers.

Bottom line -- I took what they provided and used as much as possible. I'm not comfortable going to press until you take a look at it.

- Other PHS stuff: Shelly Gordon and Barbara Garcia are following up on budget numbers, I haven't heard anything from HHS, State (I called them), Education (called them), Treasury (called them), or Jeremy.

Glen Harrelson is following up re IHS -- the have no FY 97 figures and apparently no treatment efforts.

Discussed where we stand with Gordon at OMB -- I'm going to give him the budget numbers we have now and the change pages after the ONAP review.

I'm sending a draft to you tonight via FedEx... enjoy...

I'll keep you posted about where things stand ...

Jane

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
010. email	From: Donald Abrams, To: Jeffrey Levi, Re: The Novick Saga (1 page)	07/22/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
011. email	From: Jeffrey Levi, To: Kaplan@mppm.som.yale.edu, Re: Novick is Alive and Well (1 page)	07/22/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:22-JUL-1996 11:12:00.00

SUBJECT: CDC AIDS Daily Summary 07/22/96

TO: levi_j (levi_j@A1@CD) (WHO)

READ:22-JUL-1996 18:32:36.37

TEXT:

AIDS Daily Summary
July 22, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

"Patents: Pharmaceutical Companies Lay Down \$25 Million in Cold Cash for Rights to Hot New AIDS Drugs"

"Tending to Patients With AIDS Teaches Valuable Lessons"

"AIDS Drugs Cloud Future for Buyers of Life Policies"

"Small Stock Focus: Gilead Sciences, BioChem Pharma"

"Across the USA: Indiana, Michigan"

"More AIDS Patients Found in Ethiopia"

"HIV-1 Infects Placenta as Early as First Trimester"

"AIDS Mortality Alters Population Projections"

"US States Must Cover Protease Inhibitors"

"Patents: Pharmaceutical Companies Lay Down \$25 Million in Cold Cash for Rights to Hot New AIDS Drugs"

New York Times (07/22/96) P. D2; Riordan, Teresa

Vertex Pharmaceuticals and Glaxo Wellcome paid a combined \$25 million to G.D. Searle earlier this month for a nonexclusive license to a patent pending for protease inhibitors. Searle, which is owned by Monsanto, had researched the new AIDS drugs, but did not pursue marketing approval. Vertex and Glaxo, meanwhile, are now collaborating on clinical trials of a drug called VX-478. The up-front payment guarantees that Searle will not sue the two companies for payment infringement when the drug is marketed.

"Tending to Patients With AIDS Teaches Valuable Lessons"

Wall Street Journal (07/22/96) P. B1; Chase, Marilyn

The AIDS epidemic has forced many adults into the role of caregiver at an earlier age than usual, as friends and loved ones fall ill in their prime years. At the XIth International Conference on AIDS, caregivers discussed the difficulty of this role, as well as the feeling of strength it gives them. Robert Washington, a mental health expert at the St. Francis Center in Washington, D.C., noted that caregiving means giving up one's own agenda and "being present" for whatever the patient needs. However, says M. Lyndon Haviland, a program coordinator at Columbia University's School of Public Health, caregivers need to remember not to neglect their own needs, so as to stave off depression and exhaustion. To do so, caregivers should delegate tasks to others, take breaks and get counseling when needed, she recommends.

"AIDS Drugs Cloud Future for Buyers of Life Policies"

Houston Chronicle (07/20/96) P. 1C; Sakson, Steve

Medical advances in AIDS treatment are impacting the viatical settlement industry, which is based on buying life insurance policies from people who are dying. To maintain the 15 percent annual returns such companies now offer investors, they may have to buy policies from only the sickest patients and pay less for all policies. The advent of protease inhibitors caused stock in viatical settlement firms to drop substantially in the past year, with National Capital Benefit's parent company losing 50 percent and Dignity Partners falling 77 percent. AIDS activists are concerned because they say that the long-term benefits of the drugs are not proven and that without the money some patients get from selling their life insurance, they may not be able to afford rent, food, or medicine.

"Small Stock Focus: Gilead Sciences, BioChem Pharma"

Wall Street Journal (07/22/96) P. C1; Lohse, Deborah

Biotechnology stocks were among those recently affected as the Nasdaq Composite Index declined. According to data from Prudential Securities, the 77 biotechnology stocks on its biotechnology index fell 21 percent. Some advisors, however, are now recommending certain biotechnology companies that have become relative bargains in the market sell-off. David Bayer of American Express Financial Advisers recommends Gilead Sciences, a leader in research on AIDS drugs, while Stefan Cobb of Sirach Capital Management recommends BioChem Pharma, a company that has seen its earnings estimates increase as its new AIDS therapy, 3TC, hits the shelves.

"Across the USA: Indiana, Michigan"

USA Today (07/22/96) P. 12A

Hemophiliacs in Indiana can sue drug companies whose blood products allegedly were contaminated with HIV, the Indiana Supreme Court ruled. In Michigan, meanwhile, an Oakland University biology professor has been reinstated following a ruling that his suspension was unfair. Prof. Rasul Chaudry had been charged with not ensuring the safety of faculty and students engaged in AIDS research.

"More AIDS Patients Found in Ethiopia"

Xinhua News Agency (07/20/96)

Blood tests of 817 Ethiopian patients in three hospitals found that 509 were infected with HIV. In Axum and Adwa hospitals, the number of HIV-positive patients has increased 30 percent over last year. According to a new report from the Ethiopian News Agency, the majority of the infected individuals are civil servants, drivers, prostitutes, and ex-servicemen. The Ethiopian National AIDS Control Department recently disclosed that there are also an estimated 350,000 people with full-blown AIDS in the country.

"HIV-1 Infects Placenta as Early as First Trimester"

Reuters (07/19/96)

HIV-1 can infect the placenta as early as the first trimester of pregnancy, reported Chiara De Andreis of Milan and colleagues in the June issue of the journal AIDS. The researchers said they found HIV in two-thirds of cord blood samples analyzed in their study of 30 HIV-positive women. They said, however, that more research was needed to determine "the source of HIV in cord blood and the possible contribution of placental or maternal cells infected with HIV to vertical transmission of the virus."

"AIDS Mortality Alters Population Projections"

1996 World Population Data Sheet of the Population Reference Bureau (06/96)

AIDS has presented itself to demographers as a disease whose long-term impact must be considered. In Africa, HIV and AIDS already appear to be altering the demographics of up to 30 nations, particularly Botswana, Kenya, Malawi, Uganda, Zambia, and Zimbabwe. The United Nations estimated in 1994 that the population of seriously affected sub-Saharan countries would be about 4 percent less in 2005 than it would have been without AIDS. However, new analysis by the U.S. Bureau of Census' International Programs Center predicts a greater impact from AIDS in some countries than had been projected. According to the forecasts, the population of sub-Saharan Africa in 2025 will be 100 million lower than what had been expected. Taking into account a moderate impact from AIDS, Africa's population could reach about 1.5 billion by 2025 and will near 2 billion by mid-century.

"US States Must Cover Protease Inhibitors"

Lancet (07/06/96) Vol. 348, No. 9019, P. 52; Barnett, Alicia Ault

The Clinton administration has informed state Medicaid programs that they must cover the three newly approved protease inhibitors. The administration also cautioned states to be careful not to "excessively or unreasonably restrict" coverage of any HIV/AIDS therapies. Sally K. Richardson, director of the Medicaid Bureau at the Department of Health and Human Services, said that limiting access to drugs needed by HIV-infected patients can have "serious ramifications, including the emergence of resistance if such drugs are discontinued."

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:22-JUL-1996 11:13:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01I7DDQP2CO0002F45@PMDf.EOP.GOV> for
levi_j@a1.eop.gov; Mon, 22 Jul 1996 11:11:58 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <01I7DDQE7Q6A00007U@STORM.EOP.GOV> for
levi_j@a1.eop.gov; Mon, 22 Jul 1996 11:11:43 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA22837; Mon,
22 Jul 1996 11:11:57 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
012. email	From: Jeffrey Levi, To: Ursula Sanville, Re: Trying Again [personal] [partial] (1 page)	07/22/1996	b(6)

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-JUL-1996 18:32:22.56

SUBJECT: RE: Trying again

TO: Ursula Sanville (SANVILLE_U) (OPD)

READ:23-JUL-1996 09:39:19.80

TEXT:

thanks...I look forward to the draft; yes INIH will need to look t
the seven goals; no we don't have to fix everything such as in
discrimination. But let's wait till we've heard from Kevin.
I have a call into Jeremy; i'll find out where things stand.
Tell Cindy Hall I have no info yet; will let her know when i do --
but have not short-term answers to this problem.
I will not be coming in tomorrow -- will try to do things via
conference call with the ADAP announcement.

(b)(6)

hope things aren't too crazy

[012]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:22-JUL-1996 16:02:32.83

SUBJECT: Things

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:22-JUL-1996 18:28:40.51

TEXT:

Hello Jeff --

Hope you are enjoying being away from the office. I'm sorry to bother you, but there some things

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:22-JUL-1996 18:33:41.46

SUBJECT: daily news

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 16:09:33.75

TO: Ursula Sanville (SANVILLE_U) (OPD)
READ:NOT READ

TO: Lahoma Romocki (ROMOCKI_L) (OPD)
READ:13-AUG-1996 15:37:37.94

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:22-JUL-1996 11:11:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 07/22/96

ATT TO: levi_j (levi_j@A1@CD)

TEXT:

AIDS Daily Summary
July 22, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

"Patents: Pharmaceutical Companies Lay Down \$25 Million in Cold Cash for Rights to Hot New AIDS Drugs"

"Tending to Patients With AIDS Teaches Valuable Lessons"

"AIDS Drugs Cloud Future for Buyers of Life Policies"

"Small Stock Focus: Gilead Sciences, BioChem Pharma"

"Across the USA: Indiana, Michigan"

"More AIDS Patients Found in Ethiopia"

"HIV-1 Infects Placenta as Early as First Trimester"

"AIDS Mortality Alters Population Projections"

"US States Must Cover Protease Inhibitors"

"Patents: Pharmaceutical Companies Lay Down \$25 Million in Cold Cash for Rights to Hot New AIDS Drugs"

New York Times (07/22/96) P. D2; Riordan, Teresa

Vertex Pharmaceuticals and Glaxo Wellcome paid a combined \$25 million to G.D. Searle earlier this month for a nonexclusive license to a patent pending for protease inhibitors. Searle, which is owned by Monsanto, had researched the new AIDS drugs, but did not pursue marketing approval. Vertex and Glaxo, meanwhile, are now collaborating on clinical trials of a drug called VX-478. The up-front payment guarantees that Searle will not sue the two companies for payment infringement when the drug is marketed.

"Tending to Patients With AIDS Teaches Valuable Lessons"

Wall Street Journal (07/22/96) P. B1; Chase, Marilyn

The AIDS epidemic has forced many adults into the role of caregiver at an earlier age than usual, as friends and loved ones fall ill in their prime years. At the XIth International Conference on AIDS, caregivers discussed the difficulty of this role, as well as the feeling of strength it gives them. Robert Washington, a mental health expert at the St. Francis Center in Washington, D.C., noted that caregiving means giving up one's own agenda and "being present" for whatever the patient needs. However, says M. Lyndon Haviland, a program coordinator at Columbia University's School of Public Health, caregivers need to remember not to neglect their own needs, so as to stave off depression and exhaustion. To do so, caregivers should delegate tasks to others, take breaks and get counseling when needed, she recommends.

"AIDS Drugs Cloud Future for Buyers of Life Policies"

Houston Chronicle (07/20/96) P. 1C; Sakson, Steve

Medical advances in AIDS treatment are impacting the viatical settlement industry, which is based on buying life insurance policies from people who are dying. To maintain the 15 percent annual returns such companies now offer investors, they may have to buy policies from only the sickest patients and pay less for all policies. The advent of protease inhibitors caused stock in viatical settlement firms to drop substantially in the past year, with National Capital Benefit's parent company losing 50 percent and Dignity Partners falling 77 percent. AIDS activists are concerned because they say that the long-term benefits of the drugs are not proven and that without the money some patients get from selling their life insurance, they may not be able to afford rent, food, or medicine.

"Small Stock Focus: Gilead Sciences, BioChem Pharma"

Wall Street Journal (07/22/96) P. C1; Lohse, Deborah

Biotechnology stocks were among those recently affected as the Nasdaq Composite Index declined. According to data from

Prudential Securities, the 77 biotechnology stocks on its biotechnology index fell 21 percent. Some advisors, however, are now recommending certain biotechnology companies that have become relative bargains in the market sell-off. David Bayer of American Express Financial Advisers recommends Gilead Sciences, a leader in research on AIDS drugs, while Stefan Cobb of Sirach Capital Management recommends BioChem Pharma, a company that has seen its earnings estimates increase as its new AIDS therapy, 3TC, hits the shelves.

"Across the USA: Indiana, Michigan"
USA Today (07/22/96) P. 12A

Hemophiliacs in Indiana can sue drug companies whose blood products allegedly were contaminated with HIV, the Indiana Supreme Court ruled. In Michigan, meanwhile, an Oakland University biology professor has been reinstated following a ruling that his suspension was unfair. Prof. Rasul Chaudry had been charged with not ensuring the safety of faculty and students engaged in AIDS research.

"More AIDS Patients Found in Ethiopia"
Xinhua News Agency (07/20/96)

Blood tests of 817 Ethiopian patients in three hospitals found that 509 were infected with HIV. In Axum and Adwa hospitals, the number of HIV-positive patients has increased 30 percent over last year. According to a new report from the Ethiopian News Agency, the majority of the infected individuals are civil servants, drivers, prostitutes, and ex-servicemen. The Ethiopian National AIDS Control Department recently disclosed that there are also an estimated 350,000 people with full-blown AIDS in the country.

"HIV-1 Infects Placenta as Early as First Trimester"
Reuters (07/19/96)

HIV-1 can infect the placenta as early as the first trimester of pregnancy, reported Chiara De Andreis of Milan and colleagues in the June issue of the journal AIDS. The researchers said they found HIV in two-thirds of cord blood samples analyzed in their study of 30 HIV-positive women. They said, however, that more research was needed to determine "the source of HIV in cord blood and the possible contribution of placental or maternal cells infected with HIV to vertical transmission of the virus."

"AIDS Mortality Alters Population Projections"
1996 World Population Data Sheet of the Population Reference Bureau (06/96)

AIDS has presented itself to demographers as a disease whose long-term impact must be considered. In Africa, HIV and AIDS already appear to be altering the demographics of up to 30 nations, particularly Botswana, Kenya, Malawi, Uganda, Zambia, and Zimbabwe. The United Nations estimated in 1994 that the population of seriously affected sub-Saharan countries would be about 4 percent less in 2005 than it would have been without AIDS.

However, new analysis by the U.S. Bureau of Census' International Programs Center predicts a greater impact from AIDS in some countries than had been projected. According to the forecasts, the population of sub-Saharan Africa in 2025 will be 100 million lower than what had been expected. Taking into account a moderate impact from AIDS, Africa's population could reach about 1.5 billion by 2025 and will near 2 billion by mid-century.

"US States Must Cover Protease Inhibitors"

Lancet (07/06/96) Vol. 348, No. 9019, P. 52; Barnett, Alicia Ault

The Clinton administration has informed state Medicaid programs that they must cover the three newly approved protease inhibitors. The administration also cautioned states to be careful not to "excessively or unreasonably restrict" coverage of any HIV/AIDS therapies. Sally K. Richardson, director of the Medicaid Bureau at the Department of Health and Human Services, said that limiting access to drugs needed by HIV-infected patients can have "serious ramifications, including the emergence of resistance if such drugs are discontinued."

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:22-JUL-1996 11:13:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <0117DDQP2CO0002F45@PMDf.EOP.GOV> for levi_j@al.eop.gov; Mon, 22 Jul 1996 11:11:58 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <0117DDQE7Q6A00007U@STORM.EOP.GOV> for levi_j@al.eop.gov; Mon, 22 Jul 1996 11:11:43 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id LAA22837; Mon, 22 Jul 1996 11:11:57 -0400

Errors-to: shelly_olim_at_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville (SANVILLE_U) (OPD)

CREATION DATE/TIME:23-JUL-1996 17:23:32.75

SUBJECT: Jeremy and ONDCP

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-JUL-1996 17:58:54.32

TEXT:

FYI, spoke to Jeremy -- he wants us to consider using the full ONDCP memo in the Strategy so as not to irritate them. Suggested making description of their efforts comparable with other Departments/Agencies, keeping the spirit of their memo -- he said ok but make sure to talk with you. I'll draft a blurb as we discussed, and we can take it from there.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Richard J. Turman (TURMAN_R) (OMB)

CREATION DATE/TIME:23-JUL-1996 12:00:56.15

SUBJECT: L/HHS postponed

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-JUL-1996 12:02:02.81

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:23-JUL-1996 11:44:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Barry T. Clendenin

ATT SUBJECT: Senate L/HHS Markup --

ATT TO: Richard J. Turman (TURMAN_R)

ATT TO: Thomas M. Reilly (REILLY_T)

ATT TO: Michelle L. Hanson (HANSON_M)

ATT TO: Ann L. Kendrall (KENDRALL_A)

ATT TO: John M. Richardson (RICHARDSON_J)

ATT TO: Barry White (WHITE_B)

ATT TO: Keith J. Fontenot (FONTENOT_K)

ATT TO: Elizabeth L. Rossman (ROSSMAN_E)

TEXT:

John Callahan of HHS just called to advise that Jack Chow called from the Subcommittee noting that the markup had been postponed until after Labor Day.

BC

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi (LEVI_J) (WHO)

CREATION DATE/TIME:23-JUL-1996 18:09:13.81

SUBJECT: press release

TO: Richard J. Turman (TURMAN_R) (OMB)

READ:23-JUL-1996 18:24:41.30

TEXT:

i could not download the press release -- it was an incompatible format. Can you fax it to me? I assume we are not rushing given the new time frame. thanks.

540-743-1728

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeremy D. Benami (BENAMI_J) (WHO)

CREATION DATE/TIME:23-JUL-1996 09:53:42.36

SUBJECT: Party reimbursements

TO: Carol H. Rasco (RASCO_C) Autoforward to: Jill Pizzuto (PIZZUTO_J) (WHO)
READ:23-JUL-1996 09:55:10.03

TO: Jennifer L. Klein (KLEIN_J) (OPD)
READ:23-JUL-1996 09:59:09.97

TO: Jill Pizzuto (PIZZUTO_J) (OPD)
READ:23-JUL-1996 09:55:10.03

TO: Julie E. Demeo (DEMEO_J) (OPD)
READ:23-JUL-1996 10:08:50.45

TO: Jeffrey Levi (LEVI_J) (WHO)
READ:23-JUL-1996 11:59:22.51

TO: Diane Regas (REGAS_D) (OPD)
READ:23-JUL-1996 13:00:38.02

TO: Cathy R. Mays (MAYS_C) (OPD)
READ:23-JUL-1996 10:20:19.12

TO: Patsy Fleming (FLEMING_P) (WHO)
READ:24-JUL-1996 16:02:07.79

CC: Elizabeth E. Drye (DRYE_E) (OPD)
READ:23-JUL-1996 18:53:30.36

CC: Stephen C. Warnath (WARNATH_S) (OPD)
READ:23-JUL-1996 09:59:52.83

TEXT:

The parties have been coming fast and furious at the DPC in the last couple of months. Your party organizing committee is trying to keep up with the expenses and reimbursements - so the following is the list of who owes what according to our records. If you paid, or if you did not attend and therefore won't be paying, please let Steve know:

We are collecting \$7 for the Debbie Mike Gaynor party. The following people still owe:

Burke
Fleming
Levi
Reed

We are collecting \$12 for the Dorothy shower

Demeo
Pizzuto
Fleming
Klein
Mays
We are collecting \$10 for Roz's goodbye
Klein
Rasco
Pizzuto
Demeo
Levi
Regas
Mays
Fleming

Please accept our apologies if there is a mistake. It is difficult to keep track. Please try to either settle with Steve or let him know that our notes are wrong ASAP. Thanks.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
013. email	From: Edward Kaplan, To: Jeffrey Levi, Re: Novick is Alive and Well (2 pages)	07/23/1996	Personal Misfile

COLLECTION:

Clinton Presidential Records
Automated Records Management System [Email]
WHO ([Jeffrey Levi...])
OA/Box Number: 500000

FOLDER TITLE:

[07/16/1996 - 07/23/1996]

2018-0759-F

jn423

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Richard J. Turman (TURMAN_R) (OMB)

CREATION DATE/TIME:23-JUL-1996 11:40:14.94

SUBJECT: DRAFT Press Release -- Here is LH's version

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-JUL-1996 12:02:25.69

TO: Nancy S. Ridenour (RIDENOUR_N) (OMB)

READ:23-JUL-1996 11:40:39.78

CC: Maria D. Gutierrez (GUTIERREZ_M) (OMB)

READ:23-JUL-1996 11:46:11.35

CC: Barry T. Clendenin (CLENDENIN_B) (OMB)

READ:23-JUL-1996 12:01:47.73

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:23-JUL-1996 10:19:00.00

ATT BODYPART TYPE:B

ATT CREATOR: LAWRENCE J. HAAS

ATT SUBJECT: AIDS draft press release

ATT TO: Richard J. Turman (TURMAN_R)

TEXT:

As attached. Stay in touch.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:23-JUL-1996 10:19:00.00

ATT BODYPART TYPE:p

ATT CREATOR: LAWRENCE J. HAAS

TEXT:

Unable to convert OA\$SHARB2238:ZWKEERPZS.FGN to ASCII,

The following is a HEX DUMP:

===== END ATTACHMENT 2 =====

D R A F T

Press Release

President Clinton announced today that he is raising his 1997 budget request for State AIDS drug assistance programs (ADAP) by \$65 million to help Americans living with the human immunodeficiency virus (HIV) to get life-saving prescription drugs.

"New classes of drugs and new methods of treatment hold out the possibility that we can halt the progress of HIV and begin to repair the health of those who are living with this virus," the President said. "Therefore, it is important to take action to do so."

The President's announcement comes at a time of great hope and opportunity in the battle against HIV and AIDS, as illustrated by the scientific advances discussed earlier this month at the Eleventh International Conference on AIDS in Vancouver, Canada.

State ADAP programs help about 65,000 low-income people with HIV buy recently-discovered, life-extending drug therapies; these individuals do not get Medicaid, nor do they get prescription coverage through private health insurance. The ADAP programs are partially supported by grants under the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act.

Earlier this year, after the Food and Drug Administration's rapid approval of the first three protease inhibitor drugs, the President asked Congress to increase the Federal commitment to ADAP by \$52 million, to \$115 million in 1996. With strong bipartisan support, Congress agreed to the request, and the money has been distributed to every state, the District of Columbia, and Puerto Rico.

Now, with the promising results reported in Vancouver, the President has increased his 1997 request to \$196 million, which would double funding for ADAP since 1995. The President also asked States to maintain their strong commitments to providing additional resources for ADAP. Similarly, the President urged pharmaceutical manufacturers, who have made an admirable investment in the development of these drugs, to continue their commitment to helping make these products available for those who need them.

"While new drug treatments offer enormous hope to people living with HIV, it is also clear that our work is far from complete," the President said.

Indeed, further research is necessary to determine the long-term effect of protease inhibitors and other drugs, the proper dosages and combination of drugs, the optimal time to begin treatment, and the potential for drug resistance. The National Institutes of Health, working closely with scientists and clinicians from medical

schools, hospitals, and the pharmaceutical industry, is committed to providing answers to these critical questions.

Without this budget amendment, thousands of Americans may lack access to the medications that hold promise for extending the lives of people with AIDS. The House has indicated an admirable bipartisan interest in boosting 1997 funding for these drugs.

The Administration looks forward to continuing to work with Congress to see that people who need these life-saving AIDS drugs can have greater access to them.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Richard J. Turman (TURMAN_R) (OMB)

CREATION DATE/TIME:23-JUL-1996 16:51:23.04

SUBJECT: AIDS Statement -- revised per HHS

TO: Jeffrey Levi (LEVI_J) (WHO)

READ:23-JUL-1996 17:55:40.58

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:23-JUL-1996 16:43:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Richard J. Turman

ATT SUBJECT: Revised AIDS Statement

ATT TO: LAWRENCE J. HAAS (HAAS_L)

ATT CC: Nancy-Ann E. Min (MIN_N)

ATT CC: Barry T. Clendenin (CLENDENIN_B)

TEXT:

Here it is, reflecting HHS' edits.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:23-JUL-1996 16:43:00.00

ATT BODYPART TYPE:p

ATT CREATOR: Richard J. Turman

TEXT:

Unable to convert OA\$SHARC1426:ZWKENXEKK.FGN to ASCII,
The following is a HEX DUMP:

===== END ATTACHMENT 2 =====

D R A F T

Press Release

President Clinton announced today that he is raising his 1997 budget request for State AIDS drug assistance programs (ADAP) by \$65 million to help Americans living with the human immunodeficiency virus (HIV) to get life-saving prescription drugs.

"New classes of drugs and new methods of treatment hold out the possibility that we can halt the progress of HIV and begin to repair the health of those who are living with this virus," the President said. "Therefore, it is important to take action to do so."

The President's announcement comes at a time of great hope and opportunity in the battle against HIV and AIDS, as illustrated by the scientific advances discussed earlier this month at the Eleventh International Conference on AIDS in Vancouver, Canada.

State ADAP programs help about 69,000 low-income people with HIV buy recently-discovered, life-extending drug therapies; these individuals do not get Medicaid, nor do they get prescription coverage through private health insurance. The ADAP programs are partially supported by grants under the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act.

Earlier this year, after the Food and Drug Administration's rapid approval of the first three protease inhibitor drugs, the President asked Congress to increase the Federal commitment to ADAP by \$52 million. With strong bipartisan support, Congress agreed to the request, and the money has been distributed to every state, the District of Columbia, and Puerto Rico.

Now, with the promising results reported in Vancouver, the President has increased his 1997 request specifically for ADAP to \$117 million, which more than doubles the amount the President is seeking specifically for these life-saving therapies. The President also asked States to maintain their strong commitments to providing additional resources for ADAP. Similarly, the President urged pharmaceutical manufacturers, who have made an admirable investment in the development of these drugs, to continue their commitment to helping make these products available for those who need them.

"While new drug treatments offer enormous hope to people living with HIV, it is also clear that our work is far from complete," the President said.

Indeed, further research is necessary to determine the long-term effect of protease inhibitors and other drugs, the proper dosages and combination of drugs, the optimal time to begin treatment, and the potential for drug resistance. The National Institutes of Health, working closely with scientists and clinicians from medical schools, hospitals, and the pharmaceutical industry, is committed to providing answers to these critical questions.

Without this budget amendment, thousands of Americans may lack access to the medications that hold promise for extending the lives of people with AIDS. The House has indicated an admirable bipartisan interest in boosting 1997 funding for these drugs.

The Administration looks forward to continuing to work with Congress to see that people who need these life-saving AIDS drugs can have greater access to them.